of the european union · information from european union institutions and bodies commission 2009/c...

I Resolutions, recommendations and opinions

RESOLUTIONS

Council

2009/C 323/01 Council Resolution of 3 December 2009 on the enhanced governance of the European Research Area (ERA) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1

II Information

INFORMATION FROM EUROPEAN UNION INSTITUTIONS AND BODIES

Commission

2009/C 323/02 Authorisation for State aid pursuant to Articles 87 and 88 of the EC Treaty — Cases where the Commission raises no objections ( 1 ) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 5

2009/C 323/03 Authorisation for State aid pursuant to Articles 107 and 108 TFEU — Cases where the Commission raises no objections ( 1 ) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 8

ISSN 1725-2423 C 323

Volume 52

31 December 2009 Information and Notices

( 1 ) Text with EEA relevance (Continued overleaf)

Official Journal of the European Union

English edition

Notice No Contents

Price: EUR 3 EN

Page

This issue closes the C series for 2009.

http://eur-lex.europa.eu/LexUriServ/LexUriServ.do?uri=OJ:C:2009:323:0001:0004:EN:PDF



2009/C 323/04 Communication from the Commission — Guideline on the operation of the procedures laid down in Chapters II, III and IV of Commission Regulation (EC) No 1234/2008 concerning the examination of variations to the terms of marketing authorisations for medicinal products for human use and veterinary medicinal products . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 9

IV Notices

NOTICES FROM EUROPEAN UNION INSTITUTIONS AND BODIES

Commission

2009/C 323/05 Euro exchange rates . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 23

2009/C 323/06 Commission Communication concerning the implementation of Article 4 of Regulation (EC) No 552/2004 of the European Parliament and of the Council of 10 March 2004 on the interoperability of the European Air Traffic Management network ( 1 ) (Publication of titles and references of Community specifications under the Regulation) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 24

2009/C 323/07 Commission notice on current State aid recovery interest rates and reference/discount rates for 27 Member States applicable as from 1 January 2010 (Published in accordance with Article 10 of Commission Regulation (EC) No 794/2004 of 21 April 2004 (OJ L 140, 30.4.2004, p. 1)) . . . . . . . . . . . . . . . . . . . . . . . 25

2009/C 323/08 Commission notice concerning the date of application of the protocols on rules of origin providing for diagonal cumulation of origin between the European Union, Albania, Bosnia and Herzegovina, Croatia, the former Yugoslav Republic of Macedonia, Montenegro, Serbia and Turkey . . . . . . . . . . . . . . . . . . . . . . . . 26

NOTICES FROM MEMBER STATES

2009/C 323/09 Information by the European Commission on a list of States and their competent authorities, published in accordance with Article 22(2) of Council Regulation (EC) No 1005/2008, and concerning Article 20(1), (2), (3) and Annex III to Regulation (EC) No 1005/2008 on Flag State notifications . . . . . . . . . 28

EN

Notice No Contents (continued)

( 1 ) Text with EEA relevance (Continued on inside back cover)

Page







I

(Resolutions, recommendations and opinions)

RESOLUTIONS

COUNCIL

COUNCIL RESOLUTION

of 3 December 2009

on the enhanced governance of the European Research Area (ERA)

(2009/C 323/01)

THE COUNCIL OF THE EUROPEAN UNION,

RECALLS its Resolution of 14 January 1974 on the coordination of national policies and the definition of projects of interest to the Union in the field of science and technology which established a Scientific and Technical Research Committee (CREST) ( 1 ), replaced by Council Resolution of 28 September 1995 on CREST ( 2 );

RECALLS its Resolution of 15 June 2000 establishing a European Research Area (ERA) ( 3 ) following the European Council of 23 and 24 March 2000 which agreed on the Lisbon Strategy;

RECALLS the conclusions of the European Council of 8 and 9 March 2007 which referred to the notion of well functioning Knowledge Triangle in the form of interaction between education, research and innovation, and of 19 and 20 March 2009 which called for urgent concrete measures to encourage partnership between business, research, education and training and to step up and improve the quality of investment in research, knowledge and education;

RECALLS the conclusions of the European Council of 13 and 14 March 2008 which called upon the Member States to remove barriers to the free movement of knowledge by creating a ‘fifth freedom’;

RECALLS its Conclusions of 30 May 2008 on the launch of the ‘Ljubljana Process — Towards full realisation of ERA’ aiming to establish an enhanced governance for the ERA based on a long-term vision on ERA developed in partnership by Member States and the Commission with broad support from stakeholders and citizens;

RECALLS its Conclusions of 2 December 2008 on the definition of a 2020 vision for the European Research Area ( 4 ) which invited future Presidencies to take this vision and its potential evolution into consideration in the development of their proposals for the future governance of the ERA and stressed the need to use the full potential of existing coordination structures such as CREST in dealing with ERA initiatives;

EN 31.12.2009 Official Journal of the European Union C 323/1

( 1 ) OJ C 7, 29.1.1974, p. 2. ( 2 ) OJ C 264, 11.10.1995, p. 4. ( 3 ) OJ C 205, 19.7.2000, p. 1. ( 4 ) OJ C 25, 31.1.2009, p. 1.

RECALLS the conclusions of the European Council of 11 and 12 December 2008, which called for the launching of a European plan for innovation, together with the development of the ERA and with reflection on the future of the Lisbon Strategy beyond 2010;

RECALLS its conclusions of 29 May 2009, to establish and regularly update a Roadmap for the implementation of the ERA Vision 2020 and to further engage in ensuring enhanced complementarity and synergies between EU policies and instruments such as the RTD Framework Programmes, the Competitiveness and Innovation Framework Programme, Structural Funds, the Ljubljana Process, the Common Framework on Education and Training and the Bologna Process.

1. ACKNOWLEDGES that research policies, programmes and activities at European level encompasses those at Union and inter-governmental levels as well as those at national/regional level which contribute to the overall development of ERA, and that third countries are also involved, when appropriate and subject to specific arrangements, in the development of ERA, while acknowledging the current status of cooperation with countries associated to the Framework Programme;

2. ACKNOWLEDGES that a large number of actors and stakeholders are already involved in the development of the ERA at national, regional, inter governmental and Union level and that various ERA- related mechanisms, processes and instruments are already in operation;

3. RECOGNISES the need for an efficient and enhanced governance for strategic policy development and decision-making in the ERA in which the Union and the Member States demonstrate more leadership and commitment for the achievement of the ERA Vision 2020 and the implementation of the post 2010 EU strategy for competitiveness and growth. Guiding principles should be simplicity, efficiency and transparency, while respecting the principle of subsidiarity;

4. UNDERLINES that this enhanced governance should aim at facilitating cooperation and coordination of ERA related activities, programmes and policies at all levels on the basis of objectives derived from the ERA Vision 2020, taking into account the positive aspects of diversity which exist in Member States;

5. RECOGNISES that the Knowledge Triangle of education, research and innovation relates to the need for improving the impact of investments in the three forms of activity by systemic and continuous interaction;

6. RECOGNISES that a crucial aspect of governance is the need to develop more coherent policy-making at European and Member State level by developing better and more efficient interaction between the three components of the Knowledge Triangle in the policy making process, to accelerate the transition to a true knowledge-based economy and society;

7. EMPHASISES the need for a more systematic, broader and structured consultation of relevant stakeholders in the ERA as well as the necessity to better communicate the aims, benefits and achievements of ERA and its Vision 2020 to the broader public and relevant categories of stakeholders;

8. Given the broad and inter-institutional nature of the ERA, EMPHASISES the need for regular exchange of views and interaction with the European Parliament;

9. ENCOURAGES Member States, where necessary, to strengthen their preparation of the meetings of relevant committees and groups (including through appropriate consultations with stakeholders) as well as to facilitate the necessary interaction between all areas of the Knowledge Triangle;

EN C 323/2 Official Journal of the European Union 31.12.2009

10. RECOGNISES the need to establish the means to provide fresh and innovative impetus on the political level in order to be able to achieve the goals of the ERA; and INVITES future Presidencies to consider convening well prepared and focused ERA Ministerial conferences when there is a clear added value providing orientations for a long-term strategic view on ERA; AGREES that such conferences could take the form of an broadened informal meeting of Ministers;

11. ACKNOWLEDGES the role that CREST has already played in providing advice to the Council and the Commission on ERA-related matters; RECOGNISES, however, that for the development of ERA and in order to respond to the need to better involve national policies, CREST should play a more proactive role as an ERA Policy Committee providing strategic timely advice to the Council, the Commission and Member States on its own initiative or on the request of the Council or the Commission;

12. On this basis, ENDORSES the following principles to strengthen the role of new CREST in the strategic development of ERA:

(a) CREST is a strategic advisory body whose function is to advise the Council, the Commission and the Member States on ERA related issues. CREST should also monitor the progress of ERA, including the EU Framework Programmes;

(b) CREST should provide strategic advice in particular on:

(i) broad orientations for possible future policies at international, European and national levels to contribute to the development of the ERA;

(ii) at an early stage, the strategic priorities, the design and implementation of policy initiatives to develop the ERA, including the EU Framework Programmes and other relevant EU initiatives, as well as relevant national and intergovernmental initiatives, including the overall coherence across the instruments and initiatives;

(iii) promoting, when relevant, the coordination of national policies relevant for the development of ERA;

(iv) at a later stage, the design and implementation of independent assessment and evaluation of all these policy initiatives.

(c) CREST should develop interactions and coherence with other policy areas, in particular those related to the Knowledge Triangle;

(d) CREST should cooperate and consult with ERA-related groups, as necessary to attain its objectives. It could also base its deliberations on input from these groups;

(e) Member States and the Commission should jointly contribute to the work of CREST for further development of ERA;

13. CONSIDERS that the working methods of CREST, taking into account the new legal and institutional framework with a view to replacing the Resolution of 28 September 1995 with a new Resolution providing a revised mandate for the CREST committee, should be further discussed. This revised mandate should be drawn up in accordance with the principles set out in paragraph 12 and approved by the Council by mid-2010;


14. INVITES all relevant groups ( 1 ), established with a view to helping deliver the ERA to develop systematic and transparent consultations with stakeholders, as appropriate;

15. INVITES Member States and the Commission to initiate a review of the ERA related groups before the end of 2010.

16. INVITES the Commission to:

— continue and further develop systematic and structured consultations with Member States, and other relevant stakeholders in a transparent manner,

— develop, jointly with the Member States, an effective ERA information system as a support tool for decision makers.


( 1 ) Currently comprising notably CREST, its dedicated configurations High Level Group on Joint Programming (GPC) and the Strategic Forum for International S&T Cooperation (SFIC), its Working Group on Knowledge Transfer, as well as the European Strategy Forum for Research Infrastructures (ESFRI) and the Steering Group for Human Resources and Mobility (SGHRM).

II

(Information)

INFORMATION FROM EUROPEAN UNION INSTITUTIONS AND BODIES

COMMISSION

Authorisation for State aid pursuant to Articles 87 and 88 of the EC Treaty

Cases where the Commission raises no objections

(Text with EEA relevance)

(2009/C 323/02)

Date of adoption of the decision 19.11.2009

Reference number of State Aid NN 55/09

Member State Germany

Region —

Title (and/or name of the beneficiary) Mutmaßliche Beihilfen durch Insolvenzgeldzahlungen und deren Finanzierung

Legal basis §§ 183 ff. Sozialgesetzbuch III

Type of measure Aid scheme

Objective Employment

Form of aid Direct grant

Budget —

Intensity —

Duration (period) 1999-NA

Economic sectors All sectors

Name and address of the granting authority Bundesagentur für Arbeit

Other information —

The authentic text(s) of the decision, from which all confidential information has been removed, can be found at:

http://ec.europa.eu/community_law/state_aids/state_aids_texts_en.htm


Reference number of State Aid NN 60/09



Member State Latvia

Region —

Title (and/or name of the beneficiary) Latvijas Hipoteku un zemes banka

Legal basis —

Type of measure Individual aid

Objective Aid to remedy serious disturbances in the economy

Form of aid Other forms of equity intervention

Budget Annual budget: LVL 72,79 million Overall budget: LVL 72,79 million

Intensity —

Duration (period) 1.2009-NA

Economic sectors Financial intermediation

Name and address of the granting authority Latvijas Republikas Finanšu Ministrija Smilšu iela 1 Rīga, LV-1919 LATVIJA





Reference number of State Aid N 350/09

Member State Austria

Region —

Title (and/or name of the beneficiary) Ausweitung des Anwendungsbereiches der Barwertberechnungsmethode der AWS GmbH für Haftungen um das Segment „KMU-Retail“

Legal basis —


Objective Regional development, Small and medium-sized enterprises

Form of aid Guarantee

Budget —

Intensity —

Duration (period) until 31.12.2013



Economic sectors All sectors

Name and address of the granting authority Austria Wirtschaftsservice Gesellschaft mit beschränkter Haftung Ungargasse 37 1030 Wien ÖSTERREICH






Authorisation for State aid pursuant to Articles 107 and 108 TFEU

Cases where the Commission raises no objections


(2009/C 323/03)


Reference number of State Aid N 467/09

Member State Romania

Region —

Title (and/or name of the beneficiary) Schema de ajutor de stat pentru sprijinirea investițiilor în extinderea și modernizarea rețelelor de distribuție a energiei electrice și a gazelor naturale

Legal basis Schema de ajutor de stat pentru sprijinirea investițiilor în extinderea și modernizarea rețelelor de distribuție a energiei electrice și a gazelor naturale; Programul Operațional „Creșterea Competitivității” 2007-2013


Objective Regional development, Energy saving

Form of aid Direct grant

Budget Overall budget: EUR 28,4 million

Intensity 50 %

Duration (period) until 31.12.2013

Economic sectors Electricity, gas and water supply

Name and address of the granting authority Ministerul Economiei Autoritatea de Management pentru POS CCE Calea Victoriei nr. 152 010096 București ROMÂNIA






Communication from the Commission — Guideline on the operation of the procedures laid down in Chapters II, III and IV of Commission Regulation (EC) No 1234/2008 concerning the examination of variations to the terms of marketing authorisations for medicinal products for human use and

veterinary medicinal products

(2009/C 323/04)

1. INTRODUCTION

Commission Regulation (EC) No 1234/2008 of 24 November 2008, concerning the examination of variations to the terms of marketing authorisations for medicinal products for human use and veterinary medicinal products ( 1 ), hereinafter ‘the variations regulation’, was published in the Official Journal on 12 December 2008. The variations regulation aims to establish a simple, clearer and more flexible legal framework for the handling of variations to marketing authorisation of medicinal products, while ensuring a high level of protection of public and animal health.

Article 4(1)(b) of the variations regulation charges the Commission with the task of drawing up guidelines on the operation of the procedures laid down in Chapters II, III and IV of that regulation as well as on the documentation to be submitted pursuant to these procedures.

Consequently, this guideline provides details on the operation of those procedures and covers the steps to follow from the submission of an application concerning the examination of variations to the terms of a marketing authorisation to the final outcome of the procedure on the application and the timeframe and procedure for competent authorities to amend, where necessary due to an approved variation, the terms of the marketing authorisation.

This guideline should facilitate the interpretation and application of the variations regulation. In case of doubt as to the applicable rules, reference should be made to the appropriate provisions of the variations regulation.

Definitions relevant to this guideline are provided in Directive 2001/82/EC, Directive 2001/83/EC, Regulation (EC) No 726/2004 as well as in the variations regulation. In addition, for the purpose of this guideline applicants belonging to the same mother company or group of companies and applicants having concluded agreements or exercising concerted practices concerning the placing on the market of the relevant medicinal product have to be taken as the same marketing authorisation holder ( 2 ).

This guideline applies to the variations listed in Article 1(1) of the variations regulation. Where reference is made in this

guideline to the centralised procedure it applies to the handling of variations to the terms of marketing authorisations granted in accordance with Regulation (EC) No 726/2004; where reference is made to the national procedure it applies to the handling of variations to the terms of marketing authorisations granted in accordance with Directive 87/22/EEC, Articles 32 and 33 of Directive 2001/82/EC, Articles 28 and 29 of Directive 2001/83/EC, as well as to authorisations granted following a referral, as provided for in Articles 36, 37 and 38 of Directive 2001/82/EC or Articles 32, 33 and 34 of Directive 2001/83/EC, which has led to complete harmonisation. Variations to the terms of marketing authorisation granted following purely national procedures are excluded from the scope of this guideline.

Reference in this guideline to ‘Member States concerned’, in accordance with Article 2(6) of the variations regulation, means each Member State whose competent authority has granted a marketing authorisation for the medicinal products in question; reference to ‘concerned Member States’ means all Member States concerned except the reference Member State.

2. PROCEDURAL GUIDANCE ON THE HANDLING OF VARIATIONS

The handling of variations covers the following categories, defined in Article 2 of the variations regulation:

— Minor variations of Type IA.

— Minor variations of Type IB.

— Major variations of Type II.

— Extensions.

— Urgent safety restriction.

For each category mentioned above, guidance is provided on the submission of the variations, grouping of variations and handling of the variations to the terms of the marketing authorisation for medicinal products for human and veterinary use listed in Article 1(1) of the variations regulation.


( 1 ) OJ L 334, 12.12.2008, p. 7. ( 2 ) OJ C 229, 22.7.1998, p. 4.

In order to allow optimal planning, availability of resources and identification of potential procedural issues (e.g. handling of overlapping applications), marketing authorisation holders are encouraged to inform the reference Member State or the European Medicines Agency (hereinafter ‘the Agency’) ( 1 ) of upcoming variation applications for the following 6-12 months. In particular, it is recommended that, at least two months in advance, the marketing authorisation holders inform the reference Member State or the Agency about the submission of grouped variations which are not listed in Annex III of the variations regulation together with a justification for grouping.

The reference Member State or the Agency is available to address any questions which marketing authorisation holders may have regarding a particular upcoming variation application. Where appropriate, a pre-submission discussion may be organised with the reference Member State or the Agency in order to obtain further regulatory and procedural advice specifically addressing the upcoming application(s).

It must be noticed that where a group of variations consists of different types of variations, the group must be submitted and will be handled according to the ‘highest’ variation type included in the group. For instance, a group consisting of an extension and a major variation of Type II will be handled as an extension application; a group consisting of minor variations of Type IB and Type IA will be handled as a Type IB notification.

Where reference is made in this guideline to the submission of variations’ notifications or applications, the number of copies to be submitted will be made public for each type of procedure by the Agency as regards the centralised procedure and by the coordination groups, established by Article 31 of Directive 2001/82/EC as regards veterinary medicinal products and Article 27 of Directive 2001/83/EC as regards medicinal products for human use (hereinafter, ‘the coordination group’), as regards the national procedure.

Marketing authorisation holders are advised that, any information related to the implementation of a given variation should immediately be provided when requested by the relevant authority.

2.1. Minor variations of Type IA

Hereby guidance is provided on the application of Articles 7, 8, 11, 14, 17, 23 and 24 of the variations regulation to minor variations of Type IA.

The variations regulation and the ‘Commission guideline on the details of the various categories of variations’ (hereinafter referred to as ‘the Commission Classification Guideline’)

set-out a list of changes to be considered as minor variations of Type IA. Such minor variations do not require any prior approval, but must be notified by the marketing authorisation holder within 12 months following implementation (‘Do and Tell’ procedure). However, certain minor variations of Type IA require immediate notification after implementation, in order to ensure the continuous supervision of the medicinal product.

The Commission Classification Guideline clarifies the conditions which must be met in order for a change to follow a Type IA notification procedure, and specifies which minor variations of Type IA must be notified immediately following implementation.

2.1.1. Submission of Type IA notifications

Within 12 months or immediately after implementation of a minor variation of Type IA, the marketing authorisation holder must submit simultaneously to all Member States concerned or to the Agency a notification. It is possible for a marketing authorisation holder to include a minor variation of Type IA which is not subject to immediate notification in the submission of a minor variation of Type IA for immediate notification or with any other variation. The conditions laid down in Articles 7(2)(a) and 7(2)(b) of the variations regulation should be fulfilled.

The twelve months deadline to notify minor variations of Type IA allows an annual reporting for these variations, where a marketing authorisation holder submits several minor variations of Type IA which have been implemented the previous twelve months.

The marketing authorisation holder may group several minor variations of Type IA under a single notification, as established in Article 7(2) of the variations regulation. For doing so, the variations regulation allows various possible solutions; the holder may submit a group of minor variations of Type IA to the terms of one marketing authorisation under a single notification as long as they are notified at the same time to the same relevant authority. The marketing authorisation holder may also group several minor variations of Type IA to the terms of several marketing authorisations under a single notification provided those variations are the same for all marketing authorisations and they are notified at the same time to the same relevant authority.

Where annual reporting and grouping of minor variations of Type IA are combined, it may be the case that the so called ‘annual report’ includes several notifications; some of this notifications referring to single minor variations of Type IA, others referring to group of minor variations of Type IA to the terms of one marketing authorisation and others referring to group of the minor variations of Type IA to the terms of several marketing authorisation as foreseen in Article 7(2)(a) of the variations regulation.


( 1 ) Where reference is made to ‘reference Member State’ in this context, this applies to products approved via a national procedure. Where reference is made to the Agency, this applies to products approved via the centralised procedure.

Where conditions for grouping are not met, the annual report will include one notification for each variation submitted.

The notification must contain the elements listed in Annex IV of the variations regulation, presented as follows in accordance with the appropriate headings and numbering of ‘The rules governing medicinal products in the European Community’, Volume 2B, Notice to applicants (hereinafter EU-CTD) format or the Notice to applicants Volume 6B format (veterinary medicinal products when EU-CTD format is not available):

— Cover letter.

— The completed EU variation application form (published in the Notice to applicants), including the details of the marketing authorisation(s) concerned, as well as a description of all variations submitted together with their date of implementation. Where a variation is the consequence of or related to another variation, a description of the relation between these variations should be provided in the appropriate section of the application form.

— Reference to the part of the Commission Classification Guideline, indicating that all conditions and documentation requirements are met, or reference to the published Article 5 Recommendation, if applicable, used for the relevant application.

— All documentation as specified in the Commission Classification Guideline.

— In case that the variations affect the summary of product characteristics, labelling or package leaflet: the revised summary of product characteristics, labelling or package leaflet (hereinafter referred to as ‘product information’), presented in the appropriate format. Where the overall design and readability of the outer and immediate packaging or package leaflet is affected by the Type IA variation, mock-ups or specimens should be provided according to Chapter 7 of Volume 2A or 6A of the Notice to applicants or as discussed with the reference Member State or the Agency on a case-by-case basis.

For variations in the national procedure, the reference Member State should additionally receive the list of dispatch dates indicating the Type IA Variation procedure number, the dates on which the applications have been sent to each Member State concerned and confirmation that the relevant fees have been paid as required by national competent authorities.

For variations in the centralised procedure, the relevant fee for the minor variation(s) of Type IA, as provided for in Council Regulation (EC) No 297/95, should be paid in accordance with the Agency’s financial procedures.

For grouped minor variations of Type IA concerning several marketing authorisations from the same holder in accordance with Article 7 of the variations regulation, a common cover

letter and application form should be submitted together with separate supportive documentation and revised product information (if applicable) for each medicinal product concerned. This will allow the relevant authorities to update the dossier of each marketing authorisation included in the group with the relevant amended or new information.

2.1.2. Type IA variations review for national procedure

The reference Member State will review the Type IA notification within 30 days following receipt.

By Day 30, the reference Member State will inform the marketing authorisation holder and concerned Member States of the outcome of its review. In case the marketing authorisation requires any amendment to the decision granting the marketing authorisation, all Member States concerned will update the marketing authorisation within two months following the receipt of the outcome of the review sent by the reference Member State or within six months following the receipt of the outcome of the review sent by the reference Member State for minor variations of Type IA requiring immediate notification.

Where one or several minor variations of Type IA are submitted as part of one notification, the reference Member State will inform the marketing authorisation holder which variation(s) have been accepted or rejected following its review. The marketing authorisation holder shall immediately cease to apply the rejected variation(s). While in the case of minor variations of Type IA, failure to provide all necessary documentation in the application will not necessarily lead to the immediate rejection of the variation if the applicant provides any missing documentation immediately on request of the relevant authority, it should be highlighted that a minor variation of Type IA may in specific circumstances be rejected with the consequence that the applicant must cease to apply already implemented variations.

2.1.3. Type IA variations review for centralised procedure

The Agency will review the Type IA notification within 30 days following receipt, without involvement of the rapporteur for the product concerned appointed by the Committee for Medicinal Products for Human Use or by the Committee for Veterinary Medicinal Products. However, a copy of the Type IA notification will be submitted by the Agency to the rapporteur for information.

By Day 30, the Agency will inform the marketing authorisation holder and the Commission of the outcome of its review, as well as whether the Commission Decision granting the marketing authorisation requires any amendments. In such case, the Commission will update the marketing authorisation within two months or within six months for minor variations of Type IA requiring immediate notification.


Where several minor variations of Type IA are submitted as part of one notification, the Agency will clearly inform the marketing authorisation holder and the Commission which variation(s) have been accepted or rejected following its review. The marketing authorisation holder shall immediately cease to apply the rejected variation(s). While in the case of minor variations of Type IA, failure to provide all necessary documentation in the application will not necessarily lead to the immediate rejection of the variation if the applicant provides any missing documentation immediately on request of the Agency, it should be highlighted that a minor variation of Type IA may in specific circumstances be rejected with the consequence that the applicant must cease to apply already implemented variations.

Where a group of minor variations of Type IA to the terms of one marketing authorisation have been approved, the Commission will update the marketing authorisation with one single decision to cover all the approved minor variations of Type IA.

Where a group of minor variations of Type IA to the terms of several marketing authorisations have been approved, the Commission will update the marketing authorisation with one decision per marketing authorisation concerned.

2.2. Minor variations of Type IB

Hereby guidance is provided on the application of Articles 7, 9, 11, 15, 17, 23 and 24 of the variations regulation to minor variations of Type IB.

The variations regulation and the Commission Classification Guideline establish which changes are to be considered as minor variations of Type IB. Such minor variations must be notified before implementation. The marketing authorisation holder must wait a period of 30 days to ensure that the notification is deemed acceptable by the relevant authorities before implementing the change (‘Tell, Wait and Do’ procedure).

2.2.1. Submission of Type IB notifications

The marketing authorisation holder must submit simultaneously to all Member States concerned, or to the Agency, a notification for minor variations of Type IB.

Marketing authorisation holders may group the submission of several minor variations of Type IB, or group the submission of a minor variation of Type IB with other minor variations, for the same marketing authorisation into one single notification, provided that this corresponds to one of the cases listed in Annex III of the variations regulation or when this has been agreed previously with the reference Member State or the Agency.

Where the same minor variation of Type IB or the same group of minor variations as stated above affect several marketing authorisations owned by the same holder, the marketing

authorisation holder may choose to submit these variations as one application for ‘worksharing’ (see section 3 on ‘worksharing’).

The notification must contain the elements listed in Annex IV of the variations regulation, presented as follows in accordance with the appropriate headings and numbering of the EU-CTD format or the Notice to applicants Volume 6B format (veterinary medicinal products when EU-CTD format is not available):

— Cover letter.

— The completed EU variation application form (published in the Notice to applicants), including the details of the marketing authorisations(s) concerned. Where a variation is the consequence of or related to another variation, a description of the relation between these variations should be provided in the appropriate section of the application form. Where a variation is considered unclassified, a detailed justification for its submission as a Type IB notification must be included.

— Reference to the part of the Commission Classification Guideline or reference to the published Article 5 Recommendation, if applicable, used for the relevant application.

— Relevant documentation in support of the proposed variation including any documentation specified in the Commission Classification Guideline.

— For variations requested by the competent authority resulting from new data submitted e.g. pursuant to post authorisation conditions or in the framework of pharmacovigilance obligations, a copy of the request should be annexed to the cover letter.

— In case that the variations affect the summary of product characteristics, labelling or package leaflet: the revised product information presented in the appropriate format. Where the overall design and readability of the outer and immediate packaging or package leaflet is affected by the minor variation of Type IB, mock-ups or specimens should be provided according to Chapter 7 of Volume 2A or 6A of the Notice to applicants or as discussed with the reference Member State or the Agency on a case-by-case basis.

For variations in the national procedure, the reference Member State should additionally receive the list of dispatch dates indicating the Type IB Variation procedure number, the dates on which the applications have been sent to each Member States concerned and confirmation that the relevant fees have been paid as required by national competent authorities.

For variations in the centralised procedure, the relevant fee for the minor variation(s) of Type IB, as provided for in Council Regulation (EC) No 297/95, should be paid in accordance with the Agency’s financial procedures.


2.2.2. Type IB variations review for national procedure

Upon receipt of a Type IB notification, the notification will be handled as follows:

The reference Member State will check within seven calendar days whether the proposed change can be considered a minor variation of Type IB, and whether the notification is correct and complete (‘validation’) before the start of the evaluation procedure.

When the proposed variation is not considered a minor variation of Type IB following the Commission Classification Guideline or has not been classified as a minor variation of Type IB in a recommendation pursuant Article 5 of the variations regulation, and the reference Member State is of the opinion that it may have a significant impact on the quality, safety or efficacy of the medicinal product, the reference Member State will inform the concerned Member States and the marketing authorisation holder immediately.

If the concerned Member States do not disagree within further seven calendar days, the marketing authorisation holder will be requested to revise and supplement its variation application so that the requirements for a major variation of Type II application are met. Following receipt of the valid revised variation application, a Type II assessment procedure will be initiated (see section 2.3.2).

If the concerned Member States disagree with the reference Member State, the reference Member State shall take the final decision on the classification of the proposed variation having taken into account the comments received.

When the reference Member State is of the opinion that the proposed variation can be considered a minor variation of Type IB, the marketing authorisation holder will be informed of the outcome of the validation and of the start date of the procedure.

Within 30 days, following the acknowledgement of receipt of a valid notification, the reference Member State will notify the marketing authorisation holder of the outcome of the procedure. If the reference Member State has not sent the holder its opinion on the notification within 30 days following the acknowledgement of receipt of a valid notification, the notification shall be deemed acceptable.

In case of an unfavourable outcome, the marketing authorisation holder may amend the notification within 30 days to take due account of the grounds for the non-acceptance of the variation. If the marketing authorisation holder does not amend the notification within 30 days as requested, the variation shall be deemed rejected by all concerned Member States.

Within 30 days of receipt of the amended notification, the reference Member State will inform the marketing authorisation holder of its final acceptance or rejection (including the grounds for the unfavourable outcome) of the variation(s). Concerned Member States will be informed accordingly.

Where a group of minor variations were submitted as part of one notification, the reference Member State will inform the marketing authorisation holder and the concerned Member States which variation(s) have been accepted or rejected following its review.

Where necessary, the relevant authorities will update the marketing authorisation within six months following closure of the procedure by the reference Member State. However, the accepted minor variations of Type IB variation may be implemented without awaiting the update of the marketing authorisation.

2.2.3. Type IB variations review for centralised procedure

Upon receipt of a Type IB notification, the Agency will handle the notification as follows:

The Agency will check within seven calendar days whether the proposed change can be considered a minor variation of Type IB, and whether the notification is correct and complete (‘validation’) before the start of the evaluation procedure.

When the proposed variation is not considered a minor variation of Type IB following the Commission Classification Guideline or has not been classified as a minor variation of Type IB in a recommendation pursuant Article 5 of the variations regulation, and the Agency is of the opinion that it may have a significant impact on the quality, safety or efficacy of the medicinal product, the marketing authorisation holder will be informed accordingly and will be requested to revise and supplement its variation application so that the requirements for a major variation of Type II application are met. Following receipt of the valid revised variation application, a Type II assessment procedure will be initiated (see section 2.3.4).

When the Agency is of the opinion that the proposed variation can be considered a minor variation of Type IB, the marketing authorisation holder will be informed of the outcome of the validation and of the start date of the procedure.

The rapporteur will be involved in the review of the Type IB notification.

Within 30 days following the acknowledgement of receipt of a valid notification, the Agency will notify the marketing authorisation holder and the Commission of the outcome of the procedure. If the Agency has not sent the holder its opinion on the notification within 30 days following the acknowledgement of receipt of a valid notification, the notification shall be deemed acceptable.

In case of an unfavourable outcome, the marketing authorisation holder may amend the notification within 30 days to take due account of the grounds for the non-acceptance of the variation. If the marketing authorisation holder does not amend the notification within 30 days as requested, the notification will be rejected.


Within 30 days of receipt of the amended notification, the Agency will inform the marketing authorisation holder and the Commission of its final acceptance or rejection (including the grounds for the unfavourable outcome) of the variation(s) and whether the Commission Decision granting the marketing authorisation requires any amendments.

Where a group of minor variations are submitted as part of one notification, the Agency will clearly inform the marketing authorisation holder which variation(s) have been accepted or rejected following its review.

Where necessary, the Commission will update the marketing authorisation within six months following receipt of the Agency Notification. However, the accepted minor variation(s) of Type IB may be implemented without awaiting the six- monthly update of the marketing authorisation and the agreed change(s) should be included in the Annexes of any subsequent Regulatory Procedure.

Where a group of minor variations to the terms of one marketing authorisation submitted as part of one notification have been approved, the Commission will update the marketing authorisation with one single decision to cover all the approved minor variations.

2.3. Major variations of Type II

Hereby guidance is provided on the application of Articles 7, 10, 11, 13, 16, 17, 23 and 24 of the variations regulation to major variations of Type II.

The variations regulation and the Commission Classification Guideline establish which changes are to be considered as major variations of Type II. Such major variations require prior approval before implementation (‘Prior authorisation’ procedure).

2.3.1. Submission of Type II applications

Where a major variation of Type II is made, the marketing authorisation holder must submit simultaneously to all Member States concerned, or to the Agency, an application.

Marketing authorisation holders may group the submission of several major variations of Type II, or to group the submission of major variation(s) of Type II with other minor variations, for the same marketing authorisation into one single application, provided that this corresponds to one of the cases listed in Annex III of the variations regulation or when this has been agreed with the reference Member State or the Agency.

Where the same major variation of Type II or the same group of variations as stated above affect several marketing authorisations owned by the same holder, the marketing authorisation holder may choose to submit these variations as one application for ‘worksharing’ (see section 3 on ‘worksharing’).

The application must contain the elements listed in Annex IV of the Regulation, presented as follows in accordance with the appropriate headings and numbering of the EU-CTD format or the Notice to applicants Volume 6B format (veterinary medicinal products when the EU-CTD format is not available):

— Cover letter.

— The completed EU variation application form (published in the Notice to Applicants), including the details of the marketing authorisation(s) concerned. Where a variation is the consequence of or related to another variation, a description of the relation between these variations should be provided in the appropriate section of the application form.

— Reference to the part of the Commission Classification Guideline or reference to the published Article 5 Recommendation, if applicable, used for the relevant application.

— Supporting data relating to the proposed variation(s).

— Update or Addendum to quality summaries, non-clinical overviews and clinical overviews (or expert reports for veterinary medicinal products) as relevant. When non- clinical or clinical study reports are submitted, even if only one, their relevant summary(ies) should be included in Module 2.

— For variations requested by the competent authority resulting from new data submitted e.g. pursuant to post authorisation conditions or in the framework of pharmacovigilance obligations, a copy of the request should be annexed to the cover letter.

— In case that the variation affects the summary of product characteristics, labelling or package leaflet: the revised product information, presented in the appropriate format. Where the overall design and readability of the outer and immediate packaging or package leaflet is affected by the Type II variation, mock-ups or specimens should be provided according to Chapter 7 of Volume 2A or 6A of the Notice to applicants or as discussed with the reference Member State or the Agency on a case-by-case basis.

For variations in the national procedure, the reference Member State should additionally receive the list of dispatch dates indicating the Type II Variation procedure number, the dates on which the applications have been sent to each Member State concerned and confirmation that the relevant fees have been paid as required by national competent authorities.

For variations in the centralised procedure, the relevant fee for the Type II variation(s), as provided for in Council Regulation (EC) No 297/95, should be paid in accordance with the Agency’s financial procedures.


2.3.2. Type II variations assessment for national procedure

Upon receipt of a Type II application, the reference Member State will handle the application as follows:

If the application has been submitted simultaneously to all the Member States concerned and contains the elements listed in point 2.3.1, the reference Member State will acknowledge receipt of a valid application of a major variation of Type II. The procedure starts from the date of acknowledgement of the receipt of a valid application by the reference Member State shall start the procedure. The marketing authorisation holder and the concerned Member States will be informed of the timetable at the start of the procedure.

As a general rule, for major variations of Type II, a 60-day evaluation timetable will apply. This period may be reduced by the reference Member State having regard to the urgency of the matter, particularly for safety issues, or may be extended by the reference Member State to 90 days for variations concerning changes or additions to the therapeutic indication. For variations for veterinary medicinal products listed in Part 2 of Annex V of the variations regulation a 90-day timetable will apply.

The reference Member State will prepare a draft assessment report according to the communicated timetable and will circulate it to the concerned Member States for comments as well as to the marketing authorisation holder for information. The concerned Member States should send to the reference Member State, their comments on the draft assessment within the timeline as stated in the timetable.

Within the evaluation period, the reference Member State may request the marketing authorisation holder to provide supplementary information.

The procedure will be suspended until the receipt of the supplementary information. As a general rule, a suspension of one month will apply. For longer suspension the marketing authorisation holder should send a justified request to the reference Member State for agreement.

The evaluation of responses may take up to 30 or 60 days depending on the complexity and amount of data requested to the marketing authorisation holder.

The request for supplementary information should be sent to the marketing authorisation holder together with a timetable stating the date by when the marketing authorisation holder should submit the requested data and where appropriate the extended evaluation period.

After receipt of the applicant’s response, the reference Member State will prepare a draft assessment report according to the communicated timetable and will circulate it to the concerned Member States for comments as well as to the marketing authorisation holder for information. The concerned Member States should send their comments on the draft assessment report within the timeline as stated in the timetable.

2.3.3. Outcome of Type II variations assessment for national procedure

By the end of the communicated evaluation period, the reference Member State will finalise the assessment report including its decision on the application and send them to the concerned Member State.

Within 30 days following receipt of the assessment report and the decision, the concerned Member States shall recognise the decision and inform the reference Member State accordingly.

In case a concerned Member States identifies, within 30 days following receipt of the assessment report and the decision, a potential serious risk to public health, or, in the case of veterinary medicinal products, on grounds of a potential serious risk to human or animal health or to the environment, that prevents recognition of the decision, this Member State shall inform the reference Member State and give a detailed statement of the reasons for its position.

The reference Member State shall refer the application to the coordination groups for application of Article 33(3), (4) and (5) of Directive 2001/82/EC or Article 29(3), (4) and (5) of Directive 2001/83/EC to the matter of disagreement and will inform the marketing authorisation holder and the concerned Member States accordingly.

Where a grouped variations application is referred to the coordination group the whole grouped application will be suspended until a decision has been made, unless otherwise decided by the reference Member State. However, only the concerned variation(s) will be discussed by the coordination group and eventually by the Committee for Medicinal Products for Human use or the Committee for Veterinary Medicinal Products, not the whole group.

As with the initial marketing authorisation procedure, it should be noted that a referral to the coordination group by the applicant is not foreseen in the variations regulation.

The reference Member State will inform the concerned Member States and the marketing authorisation holder about the approval or rejection (including the grounds for the unfavourable outcome) of the variation(s). Where several Type II variations, or a group of Type II variation(s) with other minor variations have been submitted as one application, the reference Member State will inform the applicant and the concerned Member States which variation(s) have been accepted or rejected. The applicant may withdraw single variations from the grouped application during the procedure.

After a positive decision is communicated regarding variations with changes to the summary of product characteristics, labelling or package leaflet, the applicant should submit, within seven days, translations of the product information texts to all Member States concerned.


After approval of the variation(s), the competent authorities of the Member States concerned shall, where necessary, amend the marketing authorisation to reflect the variation(s) within two months or within 30 days when the variation leads to a six- month extension of the supplementary protection certificate as referred to in Article 13(1) and (2) of Council Regulation (EEC) No 1768/92, in accordance with Article 36 of Regulation (EC) No 1901/2006.

The accepted major variation(s) of Type II can be implemented 30 days after the marketing authorisation holder has been informed about the acceptance of the variation(s) by the reference Member State, provided that necessary documents to amend the marketing authorisation have been submitted to the Member State concerned.

Variations related to safety issues must be implemented within a time-frame agreed between the reference Member State and the holder.

2.3.4. Type II variations assessment for centralised procedure

Upon receipt of a Type II application, the Agency will handle the application as follows:

If the application submitted to the Agency contains the elements listed in point 2.3.1, the Agency will acknowledge receipt of a valid application of a major variation of Type II. By the date of acknowledgement of the receipt of a valid application, the Agency will start the procedure. The marketing authorisation holder will be informed of the adopted timetable at the start of the procedure.

As a general rule, for major variations of Type II, a 60-day evaluation timetable will apply. This period may be reduced by the Agency having regard to the urgency of the matter, particularly for safety issues, or may be extended by the Agency to 90 days for variations concerning changes or additions to the therapeutic indication. For variations for veterinary medicinal products listed in Part 2 of Annex V of the variations regulation a 90-day timetable will apply.

Within the evaluation period, the Committee for Medicinal Products for Human Use or the Committee for Veterinary Medicinal Products may request supplementary information and adopt a timetable stating the date by when the marketing authorisation holder must submit the requested data and where appropriate the extended evaluation period.

The procedure will be suspended until the receipt of the supplementary information. As a general rule, a suspension of up to one month will apply. For suspension longer than one month the marketing authorisation holder should send a justified request to the Agency for agreement by the corresponding Committee.

For any follow-on request for supplementary information, an additional procedural suspension of up to one month will be applied in general; a maximum of two months may be applied when justified.

The Committee assessment of responses may take up to 30 or 60 days depending on the complexity and amount of data to be requested to the marketing authorisation holder.

The request for supplementary information or follow-on request should be sent to the marketing authorisation holder together with the timetable stating the date by when the marketing authorisation holder must submit the requested data and where appropriate the extended evaluation period.

An oral explanation to the Committee for Medicinal Products for Human Use or the Committee for Veterinary Medicinal Products may be held at the request of the Committee or the marketing authorisation holder, where appropriate.

2.3.5. Outcome of Type II variations assessment in centralised procedure

Upon adoption of an opinion of the Committee for Medicinal Products for Human Use or the Committee for Veterinary Medicinal Products, the Agency will inform the marketing authorisation holder and the Commission within 15 days as to whether the opinion is favourable or unfavourable (including the grounds for the unfavourable outcome), as well as whether the Commission Decision granting the marketing authorisation requires any amendments. Where several Type II variations, or a group of Type II variation(s) with other minor variations have been submitted as one application, the Agency will issue an opinion reflecting the final outcome of the procedure. Such opinion will also list any variations which are not considered approvable. The applicant may withdraw single variations from the grouped application during the procedure.

The re-examination procedure set-out in Articles 9(2) and 34 (2) of Regulation (EC) No 726/2004 also applies to the opinions adopted for major variations of Type II applications.

Upon receipt of the final opinion, the Commission shall, where necessary, amend the marketing authorisation to reflect the variation(s) within two months or within 30 days when the variation leads to a six-month extension of the supplementary protection certificate.

Where a group of variations to the terms of one marketing authorisation submitted as part of one notification have been approved, the Commission will update the marketing authorisation with one single decision to cover all the approved variations.

The approved major variation(s) of Type II may only be implemented once the Commission has amended the decision granting the marketing authorisation and has notified the holder accordingly. Where any amendment of the decision granting the marketing authorisation are not required following the approval of a major variation of Type II, the approved variation may only be implemented once the marketing authorisation holder has been informed by the Commission accordingly.

Variations related to safety issues must be implemented within a time-frame agreed between the Commission and the holder.


2.4. Extensions

Annex I of the variations regulation sets-out a list of changes to be considered as extensions. As established in Article 19 of the variations regulation, such applications will be evaluated in accordance with the same procedure as for the granting of the initial marketing authorisation to which it relates. The extension will either be granted a new marketing authorisation or will be included in the initial marketing authorisation to which it relates.

2.4.1. Submission of Extensions applications

Extension applications must be submitted to all Member States concerned, or to the Agency,

Marketing authorisation holders may choose to group the submission of one or more extensions together with one or more other variations for the same product into one application, provided that this corresponds to one of the cases listed in Annex III of the variations regulation or when this has been agreed with the reference Member State or the Agency. However, no worksharing of extensions applications is foreseen in the variations regulation.

The application must be presented as follows, in accordance with the appropriate headings and numbering of the EU-CTD format or the Notice to applicants Volume 6B format (veterinary medicinal products when the EU-CTD format is not available):

— Cover letter.

— The completed EU application form (published in the Notice To Applicants).

— Supporting data relating to the proposed extension. Some guidance on the appropriate additional studies required for extension applications is available in Appendix IV to Chapter 1 of Volume 2A or 6A of the Notice to applicants.

— A full Module 1 (Part 1 for veterinary medicinal products) should be provided, with justifications for absence of data or documents included in the relevant section(s) of Module 1 or Part 1.

— Update or Addendum to quality summaries, non-clinical overviews and clinical overviews (or expert reports for veterinary medicinal products) as relevant. When non- clinical or clinical study reports are submitted, even if only one, their relevant summary(ies) should be included in Module 2.

— In case that the extension affects the summary of product characteristics, labelling or package leaflet: the revised product information, presented in the appropriate format.

For extension applications in the national procedure, the reference Member State should additionally receive the list of dispatch dates indicating the procedure number, the dates on which the applications have been sent to each Member State concerned and confirmation that the relevant fees have been paid as required by national competent authorities.

For extensions in the centralise procedure, the relevant fee for the extension(s), as provided for in Council Regulation (EC) No 297/95, should be paid in accordance with the Agency’s financial procedures.

2.4.2. Extension assessment for national procedure

Upon receipt of an extension application, it will be handled as an initial marketing authorisation application in accordance with Directive 2001/82/EC or Directive 2001/83/EC and Chapter 2 of the Notice to applicants — Volume 2A or 6A.

2.4.3. Extension assessment for centralised procedure

Upon receipt of an extension application, the Agency will handle the application as for an initial marketing authorisation application in accordance with Regulation (EC) No 726/2004.

2.5. Human influenza vaccines

Hereby guidance is provided on the application of Articles 12 and 18 of the variations regulation to the annual update of human influenza vaccines applications.

Because of the specificities inherent in the manufacturing of human influenza vaccines, a special ‘fast track’ variation procedure is applicable for the annual change in active substance for the purpose of the annual update of a human influenza vaccine in order to meet the EU recommendation for human influenza virus strain(s) vaccine composition for the coming season.

Any variations to human influenza vaccines other than the introduction of the annual update will follow the variation procedures foreseen in other sections of this Guideline. However, it is possible to handle such variations under a special urgent procedure, where necessary, in a pandemic situation as established in Article 21 of the variations regulation.

The ‘fast track’ procedure consists of two steps. The first part concerns the assessment of the administrative and quality data elements listed in Annex IV (summary of product characteristics, labelling and package leaflet, and the chemical, pharmaceutical and biological documentation). The second part concerns the assessment of the clinical data and data concerning the stability of the medicinal product.

Marketing authorisation holders are recommended to discuss the annual update submissions in advance with the reference Member State or the Agency.

2.5.1. Submission of variations for annual update of human influenza vaccines applications

Variations concerning changes to the active substance for the annual update of human influenza vaccines applications must be submitted to the reference Member State and to all concerned Member States, or to the Agency.


The application must be presented as follows, in accordance with the appropriate headings and numbering of the EU-CTD format:

— Cover letter.

— The completed EU application form (published in the Notice to applicants).

— Update or Addendum to quality summaries, non-clinical overviews and clinical overviews as relevant. When non- clinical or clinical study reports are submitted, even if only one, their relevant summary(ies) should be included in Module 2. Chemical-pharmaceutical-biological supporting data relating to the proposed variation:

A revised chemical-pharmaceutical-biological expert report or an addendum to the current expert report. Furthermore, the following data are required:

Composition of the medicinal product

Clinical trial formula(e): actual formula (new season’s strains)

Manufacturing formula: actual formula

Copy of approved specifications in a tabular format

Manufacturing process:

— seed lots: history:

— passage level

— characterisation of Haemagglutinin and Neuraminidase

— analytical protocols (including test results on seed lots)

— monovalent bulks:

— manufacturing process

— strain specific changes

— validation of critical manufacturing steps (new strain)

1. inactivation

2. splitting efficiency

Specific quality control testing: validation of SRD test for new strains.

Batch analysis results (monovalent bulks): results of the first three monovalent bulks from each working seed lot of new strains (including test for neuraminidase).

Copy of approved specifications and routine tests analytical methods in a tabular format.

Stability tests on the active substances: results from monovalent bulks where they are used for more than one year.

Stability tests on the finished product: results from the previous vaccine.

Commitment to report stability data of new vaccine if outside specifications.

Annual stability testing protocol. Clinical data supporting data relating to the proposed variation:

A revised clinical-pharmacological expert report or an addendum to the current expert report.

Results of clinical studies with the new vaccine are to be submitted as a short final report, including:

— raw data,

— characteristics of the trial population (demography, co- morbidity, co-medication),

— standardised tables for immunogenicity and reactogenicity.

The type of serological test used should be stated clearly.

Applicants are encouraged to include the following PSURs in the clinical data package:

— PSUR covering the period 1 September-30 April of the previous season,

— PSUR covering the period 1 May-31 August of the last but one season.

— The revised product information, presented in the appropriate format.

For annual update of human influenza vaccines applications in national procedure, the reference Member State should additionally receive the list of dispatch dates indicating the procedure number, the dates on which the applications have been sent to each Member States concerned and confirmation that the relevant fees have been paid as required by national competent authorities.

For annual update of human influenza vaccines applications in centralised procedure, the relevant fee for the variation as provided for in Council Regulation (EC) No 297/95 shall be paid in accordance with the Agency’s financial procedures.

2.5.2. Variations assessment for national procedure

Upon receipt of an annual variation human influenza vaccines application, the reference Member State will handle the application as follows:

The reference Member State will acknowledge receipt of a valid application of an annual variation human influenza vaccine within seven days and inform the holder and the Member States concerned of the start of the procedure.


Within a maximum of 15 days from the start of the procedure, the reference Member State will send to the concerned Member States a preliminary assessment report on the administrative data and quality documentation. Concerned Member States should send their comments on the preliminary assessment within six days.

Within the evaluation period, the reference Member State may send the holder a request for supplementary information and informed the concerned Member States accordingly. The response document should be provided within a maximum of seven days. However, the procedure will not be suspended.

The reference Member State will prepare the final assessment report including its decision on the administrative data and quality part by day 30 from the start of the procedure.

The concerned Member States shall recognize the decision on the administrative and quality data within 12 days and will inform the reference Member State accordingly. The reference Member State will inform the marketing authorisation holder about the outcome.

Following the decision on the administrative and quality data, the marketing authorisation holder, where requested by the reference Member State has a maximum of 12 days to submit the clinical documentation and data concerning stability of the medicinal product to all Member States concerned.

The reference Member State will circulate the assessment report on the clinical documentation with its final decision to the concerned Member States within seven days from receipt of the clinical data.

The concerned Member States shall recognize that final decision and adopt a decision in accordance with the final decision within the following seven days.

2.5.3. Variations assessment in centralised procedure

Upon receipt of an annual variation human influenza vaccines application, the Agency will handle the application as follows:

The Agency will acknowledge receipt of a valid application of an annual variation human influenza vaccine within seven days and inform the holder of the start of the procedure.

The Committee for Medicinal Products for Human Use has a maximum of 45 days from the start of the procedure to issue its initial opinion on the quality documentation submitted.

An adoption of a Committee for Medicinal Products for Human Use opinion or a request for supplementary information is foreseen at day 30. In case the Committee requests supplementary information, the marketing authorisation holder shall provide the answers within three days, and by day 45 the

Committee will adopt its opinion on the quality documentation. This opinion will be transmitted to the Commission that, where necessary, based on that opinion will adopt a decision on the variation to the terms of the marketing authorisation and inform the holder accordingly.

Following the opinion on the quality data, the marketing authorisation holder, where requested by the Agency, shall submit the clinical documentation and data concerning stability of the medicinal product to the Agency by day 57 at the latest. Upon receipt of this data, the Committee has a maximum of 10 days to adopt its final opinion which will be transmitted by the Agency to the Commission and to the marketing authorisation holder within a maximum of three days.

Where necessary and based on the final opinion from the Committee, the Commission will amend the decision granting the marketing authorisation and update the Community Register of Medicinal Products.

2.6. Urgent Safety Restrictions

Article 22 of the variations Regulation foresees that in the event of a risk to public health in the case of medicinal products for human use or in the event of a risk to human or animal health or to the environment in the case of veterinary medicinal products, the marketing authorisation holder may take provisional ‘urgent safety restrictions’.

Urgent safety restrictions concern interim change(s) to the product information due to a pharmacovigilance, pre-clinical safety or quality signal which raise a serious concern which the marketing authorisation holder considers could represent a risk to human or animal health or to the environment and which must therefore be communicated immediately to prescribers and users; this new information has a bearing on the safe use of the medicinal product, concerning in particular one or more of the following items in the summary of product characteristics: therapeutic indications, posology, contra-indications, warnings, target species and withdrawal periods. These urgent changes will subsequently be introduced via a corresponding variation in the marketing authorisation.

The marketing authorisation holder must immediately notify all Member States concerned, or the Agency and the Commission, of the restrictions to be introduced.

If no objections have been raised by the relevant authority or the Commission within 24 hours following receipt of that information, the urgent safety restrictions are deemed as accepted. They must be implemented within a time frame agreed between the Commission or the reference Member State and the holder.


Such urgent safety restrictions may also be imposed by the Commission (for centrally authorised medicinal products) or by the national competent authorities (for nationally authorised medicinal products) in the event of a risk to public health in the case of medicinal products for human use or in the event of a risk to human or animal health in the case of veterinary medicinal products.

The corresponding variation application reflecting the urgent safety restrictions (whether requested by the holder or imposed by the Commission or the national competent authorities) must be submitted as soon as possible within 15 days after the initiation of the urgent safety restrictions.

3. PROCEDURAL GUIDANCE ON WORKSHARING

Article 20 of the variations Regulation sets-out the possibility for a marketing authorisation holder to submit in one application the same Type IB, the same Type II variation, or the same group of variations corresponding to one of the cases listed in Annex III of the Regulation or agreed with the reference Member State or the Agency which does not contain any extension affecting more than one marketing authorisation from the same holder.

In order to avoid duplication of work in the evaluation of such variations, a worksharing procedure has been established under which one authority (the ‘reference authority’), chosen amongst the competent authorities of the Member States and the Agency, will examine the variation on behalf of the other concerned authorities.

Where at least one of the concerned marketing authorisations has been authorised via the centralised procedure, the Agency will be the reference authority (section 3.4). In all other cases, a national competent authority chosen by the coordination group, taking into account the recommendation of the holder, will act as the reference authority (section 3.2).

In order to facilitate the planning of the procedure, marketing authorisation holders are encouraged to inform the Agency or the coordination group and the proposed reference authority at least three months in advance of the submission of a variation or group of variations to be subject to a worksharing procedure.

In order to benefit from a worksharing procedure, it is expected that the same change(s) will apply to the different medicinal products concerned, with either no or limited need for assessment of a potential product-specific impact. Therefore, where the ‘same’ change(s) to different marketing authorisations require the submission of individual supportive data sets for each medicinal product concerned and separate product- specific assessment, such changes will not benefit from worksharing.

3.1. Submission of variation(s) application under worksharing

A variation or group of variations presented for worksharing should be submitted as set-out in sections 2.2-2.3 above and

should be provided as one integrated submission package covering all variations for all medicinal products. This will include a common cover letter and application form, together with separate supportive documentation for each medicinal product concerned and revised product information (if applicable) for each medicinal product concerned. This will allow the Agency and the national competent authorities to update the dossier of each marketing authorisation included in the worksharing procedure with the relevant amended or new information.

The worksharing application must be submitted to all relevant authorities, i.e. for centralised procedure, the Agency and all Member States where the products concerned are authorised.

3.2. Worksharing assessment for national procedure

When the marketing authorisation holder informs the coordination group of an upcoming worksharing procedure, the coordination group will at the following meeting decide on the reference authority, taking into account the proposal of the holder and, if applicable pursuant to the third subparagraph of Article 20(3) of the variations regulation, another relevant authority to assist the reference authority. The marketing authorisation holder will be informed by the coordination group of the decision of which national competent authority will act as reference authority.

Upon receipt of a worksharing application, the reference authority will handle the application as follows:

The reference authority will acknowledge receipt of a valid application for worksharing. Immediately after acknowledging receipt of a valid application, the reference authority will start the procedure. The marketing authorisation holder and the Member States concerned will be informed of the timetable at the start of the procedure.

In general, worksharing procedures will follow a 60-day evaluation timetable or a 90-day evaluation timetable for variations listed in Part 2 of Annex V of the variations regulation. This period may however be reduced by the reference authority having regard to the urgency of the matter, particularly for safety issues, or may be extended to 90 days evaluation timetable where variations listed in Part 1 of Annex V of the variations regulation are part of the worksharing procedure.

The reference authority prepares the a draft assessment report according to the communicated timetable and circulates it to the concerned Member States for comments as well as the marketing authorisation holder for information. Concerned Member States should send their comments to the draft assessment report within the timeline stated in the timetable.

Within the evaluation period, the reference authority may send to the marketing authorisation holder a request for supplementary information.


The procedure will be suspended until the receipt of the supplementary information. As a general rule, a suspension of up to one month will apply. For longer suspension the marketing authorisation holder should send a justified request to the reference authority for agreement.

The assessment of responses may take up to 30 or 60 days depending on the complexity and amount of data requested to the marketing authorisation holder.

The request for supplementary information should be sent to the marketing authorisation holder together with a timetable stating the date by when the marketing authorisation holder must submit the requested data and where appropriate the extended evaluation period.

After receipt of the applicant’s response, the reference authority will finalise the draft assessment report on the application and circulate it to the concerned Member States and to the marketing authorisation holder for information within the timeline as stated in the timetable. Concerned Member States should send their comments on the final draft assessment report within the timeline as stated in the timetable.

3.3. Outcome of the assessment for national procedure

Upon finalisation of the review of the variations subject to the worksharing procedure, the reference authority will issue its opinion reflecting the final outcome.

In case of a favourable decision in the worksharing application the reference authority will inform the applicant and the concerned Member States about the approval of the worksharing. Such opinion will also list any variations (e.g. as part of a group, or for a specific medicinal product) which are not considered approvable.

In case of an unfavourable decision, the reference authority will inform the applicant as well as the concerned Member States about refusal of the worksharing application (including the grounds for the unfavourable outcome).

Within 30 days following receipt of the opinion, the concerned Member States shall approve the opinion, and inform the reference Member State and amend the concerned marketing authorisations accordingly.

In case one of the concerned Member States identifies, within 30 days following receipt of the opinion, a potential serious risk to public health, or, in the case of veterinary medicinal products, a potential serious risk to human or animal health or to the environment, this Member State shall inform the reference authority accordingly and the reference authority shall refer the application to the coordination group for application of Article 33(3), (4) and (5) of Directive 2001/82/EC or Article 29(3), (4) and (5) of Directive 2001/83/EC to the matter of disagreement.

A referral to coordination group by the applicant is not foreseen in the variations regulation.

After a positive opinion is communicated regarding variations with changes to the summary of product characteristics, labelling or package leaflet, the applicant should submit, within seven days, translations of the product information texts to all Member States concerned.

Minor variation(s) of Type IB approved via a worksharing procedure, may be implemented upon receipt of the favourable opinion of the reference authority.

Major variation(s) of Type II (including those which contain grouped minor variation(s) of Type IB) approved via a worksharing procedure may be implemented 30 days after receipt of the favourable opinion from the reference authority, unless the application have been referred to the coordination group for application of Article 33(3), (4) and (5) of Directive 2001/82/EC or Article 29(3), (4) and (5) of Directive 2001/83/EC to the matter of disagreement.

Variations related to safety issues must be implemented within a time-frame agreed between the marketing authorisation holder and the reference authority.

3.4. Worksharing assessment for centralised procedure

Upon receipt of a worksharing application, the Agency will handle the application as follows:

The Agency will acknowledge receipt of a valid worksharing application. Immediately after acknowledge receipt of a valid application, the Agency shall start the procedure. The marketing authorisation holder will be informed of the adopted timetable at the start of the procedure.

The Agency will appoint a rapporteur (and in some cases also a co-rapporteur) to lead the assessment procedure.

In general, worksharing procedures will follow a 60-day evaluation timetable or a 90-day evaluation timetable for variations listed in Part 2 of Annex V of the variations regulation. This period may however be reduced by the reference authority having regard to the urgency of the matter, particularly for safety issues, or may be extended to 90 days evaluation timetable where variations listed in Part 1 of Annex V of the variations regulation are part of the worksharing procedure.

Within the evaluation period, the Committee for Medicinal Products for Human Use or the Committee for Veterinary Medicinal Products may request supplementary information and adopt a timetable stating the date by when the marketing authorisation holder must submit the requested data and the extended evaluation period, if needed.


The procedure will be suspended until the receipt of the supplementary information. As a general rule, a suspension of up to one month will apply. For suspension longer than one month the marketing authorisation holder should send a justified request to the Agency for agreement by the Committee for Medicinal Products for Human or the Committee for Veterinary Medicinal Products.

For any follow-on request for supplementary information, an additional clock-stop of up to one month will be applied in general; a maximum of two months may be applied when justified.

The Committee assessment of responses may take up to 30 or 60 days depending on the complexity and amount of data provided by the marketing authorisation holder.

The request for supplementary information or follow-on request should be sent to the marketing authorisation holder together with a timetable stating the date by when the marketing authorisation holder must submit the requested data and where appropriate the extended evaluation period.

An oral explanation to the Committee for Medicinal Products for Human Use or the Committee for Veterinary Medicinal Products can be held at the request of the relevant Committee or the marketing authorisation holder, where appropriate.

3.5. Outcome of the assessment in centralised procedure

Upon finalisation of the review of the variations subject to the worksharing procedure, the Agency will issue an opinion reflecting the final outcome of the procedure. Such opinion will also list any variations (e.g. as part of a group, or for a specific medicinal product) which are not considered approvable.

Upon adoption of the opinion of the Committee on the worksharing procedure, the Agency will inform the marketing authorisation holder, the Commission and Member States concerned (if applicable) as to whether the opinion is favourable or

unfavourable (including the grounds for the unfavourable outcome), as well as whether the Decision granting the EU marketing authorisation requires any amendments.

The re-examination procedure set-out in Articles 9(2) and 34(2) of Regulation (EC) No 726/2004 also applies to opinions adopted for worksharing procedures.

Upon receipt of the final opinion, the Commission shall, where necessary, amend the EU authorisations within 30 days and the Member States concerned (if applicable) shall approve the final opinion, inform the Agency accordingly and where necessary, amend the national marketing authorisations within 30 days, unless a referral procedure in accordance with Article 35 of Directive 2001/82/EC or Article 31 of Directive 2001/83/EC is initiated within 30 days following receipt of the final opinion.

For a worksharing application to the terms of several marketing authorisations owned by the same holder, the Commission decision will apply only for centrally authorised products. If the variation concerns more than one centrally authorised product, the update to marketing authorisations will be one decision per centrally authorised product.

Minor variations of Type IB approved via the worksharing procedure, may be implemented upon receipt of the favourable opinion.

Major variation(s) of Type II (including those which contain grouped minor variation(s) of Type IB) approved via a worksharing procedure may be implemented 30 days after receipt of the favourable opinion from the Agency, unless a referral procedure in accordance with Article 35 of Directive 2001/82/EC or Article 31 of Directive 2001/83/EC is initiated within 30 days following receipt of the final opinion

Variations related to safety issues must be implemented within a time-frame agreed between the marketing authorisation holder and the Commission.


IV

(Notices)

NOTICES FROM EUROPEAN UNION INSTITUTIONS AND BODIES

COMMISSION

Euro exchange rates ( 1 )

30 December 2009

(2009/C 323/05)

1 euro =

Currency Exchange rate

USD US dollar 1,4338

JPY Japanese yen 132,35

DKK Danish krone 7,4415

GBP Pound sterling 0,90400

SEK Swedish krona 10,2953

CHF Swiss franc 1,4878

ISK Iceland króna

NOK Norwegian krone 8,3220

BGN Bulgarian lev 1,9558

CZK Czech koruna 26,400

EEK Estonian kroon 15,6466

HUF Hungarian forint 272,10

LTL Lithuanian litas 3,4528

LVL Latvian lats 0,7093

PLN Polish zloty 4,1249

RON Romanian leu 4,2325

TRY Turkish lira 2,1690

Currency Exchange rate

AUD Australian dollar 1,6036

CAD Canadian dollar 1,5039

HKD Hong Kong dollar 11,1187

NZD New Zealand dollar 1,9969

SGD Singapore dollar 2,0140

KRW South Korean won 1 669,56

ZAR South African rand 10,6001

CNY Chinese yuan renminbi 9,7861

HRK Croatian kuna 7,3066

IDR Indonesian rupiah 13 511,53

MYR Malaysian ringgit 4,9122

PHP Philippine peso 66,226

RUB Russian rouble 43,5000

THB Thai baht 47,810

BRL Brazilian real 2,4934

MXN Mexican peso 18,6896

INR Indian rupee 67,0600


( 1 ) Source: reference exchange rate published by the ECB.

Commission Communication concerning the implementation of Article 4 of Regulation (EC) No 552/2004 of the European Parliament and of the Council of 10 March 2004 on the interoperability

of the European Air Traffic Management network ( 1 )


(Publication of titles and references of Community specifications under the Regulation)

(2009/C 323/06)

Organisation Reference Edition number Title of the Community specifications Edition date

Eurocontrol ( i ) Spec-0136 2.0 EUROCONTROL Specification on the Air Traffic Services Message Handling System (AMHS) ( ii )

18.9.2009

( i ) European Organisation for the Safety of Air Navigation: Rue de la Fusée 96, 1130 Brussels, BELGIUM. Tel. +32 27299011, fax +32 27295190

( ii ) http://www.eurocontrol.int/ses/public/standard_page/fmtp_spec.html


( 1 ) OJ L 96, 31.3.2004, p. 26.

http://www.eurocontrol.int/ses/public/standard_page/fmtp_spec.html

Commission notice on current State aid recovery interest rates and reference/discount rates for 27 Member States applicable as from 1 January 2010

(Published in accordance with Article 10 of Commission Regulation (EC) No 794/2004 of 21 April 2004 (OJ L 140, 30.4.2004, p. 1))

(2009/C 323/07)

Base rates calculated in accordance with the Communication from the Commission on the revision of the method for setting the reference and discount rates (OJ C 14, 19.1.2008, p. 6). Depending on the use of the reference rate, the appropriate margins have still to be added as defined in this communication. For the discount rate this means that a margin of 100 basispoints has to be added. The Commission Regulation (EC) No 271/2008 of 30 January 2008 amending the implementing Regulation (EC) No 794/2004 foresees that, unless otherwise provided for in a specific decision, the recovery rate will also be calculated by adding 100 basispoints to the base rate.

Modified rates are indicated in bold.

Previous table published in OJ C 289, 28.11.2009, p. 6.

From To AT BE BG CY CZ DE DK EE EL ES FI FR HU IE IT LT LU LV MT NL PL PT RO SE SI SK UK

1.1.2010 … 1,24 1,24 4,92 1,24 2,39 1,24 1,88 6,94 1,24 1,24 1,24 1,24 7,03 1,24 1,24 8,70 1,24 15,11 1,24 1,24 4,49 1,24 9,92 1,02 1,24 1,24 1,16

EN 31.12.2009

Official Journal of the European U

nion C 323/25

Commission notice concerning the date of application of the protocols on rules of origin providing for diagonal cumulation of origin between the European Union, Albania, Bosnia and Herzegovina,

Croatia, the former Yugoslav Republic of Macedonia, Montenegro, Serbia ( 1 ) and Turkey

(2009/C 323/08)

For the purpose of the creation of diagonal cumulation of origin among the European Union, Albania, Bosnia and Herzegovina, Croatia, the former Yugoslav Republic of Macedonia, Montenegro, Serbia and Turkey, the European Union and the countries concerned notify each other, through the European Commission, of the origin rules in force with the other countries.

Based on the notifications received from the countries concerned, the table here enclosed gives an overview of the protocols on rules of origin providing for diagonal cumulation specifying the date from which such cumulation becomes applicable. This table replaces the previous one (OJ C 154, 7.7.2009, p. 5).

The Interim Agreement on trade and trade-related matters between the European Community and the Republic of Serbia, which was implemented unilaterally by Serbia since 30 January 2009, is implemented by the European Union as of 8 December 2009. Therefore, European Union traders are hereby informed that the Notice on trade between Serbia and the European Union published on 7 April 2009 ( 2 ) is no longer relevant.

It is recalled that cumulation can only be applied if the countries of final manufacture and of final destination have concluded free trade agreements, containing identical rules of origin, with all the countries participating in the acquisition of originating status, i.e. with all the countries in which all the materials used originate. Materials originating in a country which has not concluded an agreement with the countries of final manufacture and of final destination must be treated as non-originating.

It is also recalled that the materials originating in Turkey covered by the EU/Turkey customs union can be incorporated as originating materials for the purpose of diagonal cumulation between the European Union and the countries participating in the Stabilisation and Association Process with which an origin protocol is in force.

The ISO-Alpha-2 codes for countries listed in the table are given here below:

— Albania AL

— Bosnia and Herzegovina BA

— Croatia HR

— The former Yugoslav Republic of Macedonia MK (*)

— Montenegro ME

— Serbia RS

— Turkey TR


( 1 ) Albania, Bosnia and Herzegovina, Croatia, the former Yugoslav Republic of Macedonia, Montenegro and Serbia are the countries participating in the Stabilisation and Association Process.

( 2 ) OJ C 83, 7.4.2009, p. 28. (*) ISO code 3166. Provisional code which does not prejudge in any way the definitive nomenclature for this country,

which will be agreed following the conclusion of negotiations currently taking place under the auspices of the United Nations.

EN 31.12.2009

Official Journal of the European U

nion C 323/27

Date of application of the protocols on rules of origin providing for diagonal cumulation between the European Union, Albania, Bosnia and Herzegovina, Croatia, the former Yugoslav Republic of

Macedonia, Montenegro, Serbia and Turkey

EU AL BA HR MK ME RS TR

EU 1.1.2007 1.7.2008 1.1.2007 1.1.2008 8.12.2009 (1 )

AL 1.1.2007 22.11.2007 22.8.2007 26.7.2007 26.7.2007 24.10.2007

BA 1.7.2008 22.11.2007 22.11.2007 22.11.2007 22.11.2007 22.11.2007

HR 22.8.2007 22.11.2007 22.8.2007 22.8.2007 24.10.2007

MK 1.1.2007 26.7.2007 22.11.2007 22.8.2007 26.7.2007 24.10.2007 1.7.2009

ME 1.1.2008 26.7.2007 22.11.2007 22.8.2007 26.7.2007 24.10.2007

RS 8.12.2009 24.10.2007 22.11.2007 24.10.2007 24.10.2007 24.10.2007

TR (1 ) 1.7.2009

(1 ) For goods covered by the EU-Turkey customs union, the date of application is 27 July 2006.

NOTICES FROM MEMBER STATES

Information by the European Commission on a list of States and their competent authorities, published in accordance with Article 22(2) of Council Regulation (EC) No 1005/2008, and concerning Article 20(1), (2), (3) and Annex III to Regulation (EC) No 1005/2008 on Flag State

notifications

(2009/C 323/09)

In accordance with Article 20(1), (2), (3) and Annex III of Council Regulation (EC) No 1005/2008 ( 1 ), the following third countries have notified to the European Commission the public authorities which, in relation with the catch certification scheme established by Article 12 of the Regulation, are empowered to:

(a) register fishing vessels under their flag;

(b) grant, suspend and withdraw fishing licences to their fishing vessels;

(c) attest the veracity of information provided in the catch certificates referred to in Article 12 and validate such certificates;

(d) implement, control and enforce laws, regulations and conservation and management measures which must be complied with by their fishing vessels;

(e) carry out verifications of such catch certificates to assist the competent authorities of the Member States through the administrative cooperation referred to in Article 20(4);

(f) communicate sample forms of their catch certificates in accordance with the specimen in Annex II; and

(g) update such information.

Third country Competent authorities

ALBANIA a): — Albanian General Harbour Masters (Ministry of Public Work, Transportation and Telecom

munication) b): — National Licensing Centre (Ministry of Economy, Trade and Energy) c), d), e): — Fishery Inspectorate (Ministry of Environment, Forestry and Water Administration) f), g): — Directorate of Fisheries Policies (Ministry of Environment, Forestry and Water Administration)

ARGENTINA a) to f): — Subsecretario de Pesca y Acuicultura — Director Nacional de Coordinación Pesquera g): — Embajada Argentina ante la UE

BENIN a): — Direction de la Marine Marchande b) to g): — Direction des Pêches

CAMEROON a): — Ministère des Transports b) to g): — Ministère de l'Elevage, des Pêches et Industries Animales

CANADA a) to g): — Assistant Deputy Minister of Fisheries and Aquaculture


( 1 ) OJ L 286, 29.10.2008, p. 1.


CAPE VERDE a): — Institut Maritime et Portuaire b), d), f), g): — Direction Générale des Pêches c), e): — Direction Générale des Pêches — Institut National Développement des Pêches

CHILE a): — Dirección General del Territorio Marítimo y Marine Mercante de la Armada de Chile b): — Subsecretaría de Pesca c) to g): — Servicio Nacional de Pesca

CHINA a) to g): — Bureau of Fisheries

COLOMBIA a): — Dirección General Marítima b) to f): — Instituto Colombiano de Desarrollo Rural g): — Director de Pesca y Acuicultura

COSTA RICA a): — Oficina de Bienes Muebles b): — Presidente Ejecutivo, Instituto Costarricense de Pesca y Acuicultura c) and f): — Dirección General Técnica, Instituto Costarricense de Pesca y Acuicultura d): — Unidad de Control Pesquero, Instituto Costarricense de Pesca y Acuicultura — Director General del Servicio Nacional de Guardacostas e): — Departamento de Cooperación Internacional, Instituto Costarricense de Pesca y Acuicultura g): — Ministro de Agricultura y Ganadería

CROATIA a) to g): — Department of Fisheries, Ministry of Agriculture, Fishery and Rural Development

ECUADOR a), c), e): — Director de Gestión Pesquera b): — Director General de Pesca d): — Director de Control Pesquero f), g): — Subsecretario de Recursos Pesqueros

EL SALVADOR a): — Autoridad Marítima Portuaria b) to g): — Centro de Desarrollo de la Pesca y la Acuicultura

ERITREA a), f): — Ministry of Fisheries b): — Fisheries Resource Regulatory Department c): — Fish Quality Inspection Division d): — Monitoring Controlling and Surveillance, Ministry of Fisheries e): — Liaison Division, Ministry of Fisheries g): — Government of the State of Eritrea



FALKLAND ISLANDS

a): — Registrar of Shipping, Customs and Immigration Department b) to g): — Director of Fisheries, Fisheries Department

FAEROE ISLANDS a): — FAS Froe Islands National and International Ship Register b): — Ministry of Fisheries — Faeroe Islands Fisheries Inspection d): — Ministry of Fisheries — The Faeroe Islands Fisheries Inspection — The Police and Public Prosecution Authority e): — The Faeroe Islands Fisheries Inspection f), g): — Ministry of Fisheries

FIJI a): — Fiji Islands Maritime and Safety Administration b) to f): — Fisheries Department g): — Ministry of Health

GABON a), b): — Ministre de l'Economie Forestière, des Eaux et de la Pêche c) to g): — Directeur Général des Pêches et de l'Aquaculture

GAMBIA a): — The Gambia Maritime Administration b) to g): — Director of Fisheries

GHANA a) to g): — Directorate of Fisheries

GUATEMALA a), d): — Unidad de Manejo de la Pesca y Acuicultura b), c), e), f), g): — Ministerio de Agricultura, Ganadería y Alimentación

GUINEA a): — Agence Nationale de Navigation Maritime b): — Direction Nationale de la Pêche Maritime c), d), f): — Centre National de Surveillance et de Protection des Pêches e): — Service Industries Assurance Qualité des Produits de la Pêche et de l'Aquaculture g): — Ministère de la Pêche et de l'Aquaculture

GUYANA a) to g): — Fisheries Department

GREENLAND a): — The Danish Maritime Authority b) to g): — The Greenland Fisheries Licence Control Authority

ICELAND a), b): — Directorate of Fisheries c), e), f), g): — Directorate of Fisheries — The Icelandic Food and Veterinary Authority d): — Directorate of Fisheries — The Icelandic Coast Guards



INDONESIA a), b):

— Heads of Marine and Fisheries Services Province

— Director General of Capture Fisheries

c):

— Heads of Fishing Ports, Directorate General of Capture Fisheries

— Fisheries Inspectors, Directorate General of Marine and Fisheries Resources Surveillance and Control

d):

— Director General of Marine and Fisheries Resources, Surveillance and Control

e):

— Director General of Capture Fisheries

f), g):

— Director General of Fisheries Product Processing and Marketing

IVORY COAST a):

— Directeur des Affaires Maritimes et Portuaires

b), f), g):

— Ministre de la Production Animale et des Ressources Halieutiques

c), e):

— Service d'Inspection et de Contrôles Sanitaires Vétérinaires en Frontières

d):

— Directeur des Productions Halieutiques

JAPAN a):

— Fisheries Management Division, Bureau of Fisheries, Department of Fisheries and Forestry, Hokkaido Government Aomori Prefectural Government

— Hachinohe Fisheries Office, Sanpachi District Administration Office, Aomori Prefectural Government

— Mutsu Fisheries Office, Department of Agriculture, Forestry and Fisheries, Seihoku District Administration Office, Aomori Prefectural Government

— Ajigasawa Fisheries Office, Department of Agriculture, Forestry and Fisheries, Seihoku District Administration Office, Aomori Prefectural Government

— Fisheries Industry Promotion Division, Department of Agriculture, Forestry and Fisheries, Iwate Prefectural Government

— Fisheries Department, Kuji Regional Promotion Bureau, Iwate Prefectural Government

— Fisheries Department, Miyako Regional Promotion Bureau Iwate Prefectural Government

— Fisheries Department, Kamaishi Regional Promotion Bureau, Iwate Prefectural Government

— Fisheries Department, Ofunato Regional Promotion Bureau, Iwate Prefectural Government

— Fisheries Industry Promotion Division, Agriculture Forestry and Fisheries Department, Miyagi Prefectural Government

— Fisheries and Fishing Ports Division, Department of Agriculture, Forestry and Fisheries, Akita Prefectural Government

— Fisheries Division, Industrial and Economic Affairs Department Shonai Area General Branch Administration Office, Yamagata Prefectural Government

— Fishery Division, Fukushima Prefectural Government

— Fishery Office, Fukushima Prefectural Government

— Fisheries Administration Division, Ibaraki Prefectural Government

— Marine Industries Promotion Division, Chiba Prefectural Government



— Fishery section, Agriculture, Forestry and Fishery Division, Bureau of Industrial and Labor Affairs, Tokyo Metropolitan Government

— Fisheries Division, Environment and Agriculture Department, Kanawaga Prefectural Government

— Fisheries Division, Department of Agriculture, Forestry and Fisheries, Niigata Prefectural Government

— Promotion Division, Agriculture, Forestry and Fisheries Promotion Department, Sado Regional Promotion Bureau, Niigata Prefectural Government

— Fisheries and Fishing Port Division, Toyama Prefectural Government

— Fishery Division, Agriculture, Forestry and Fisheries Department, Ishikawa Prefectural Government

— Fisheries Division, Department of Agriculture, Forestry and Fisheries, Fukui Prefectural Government

— Reinan Regional Promotion Bureau, Fukui Prefectural Government

— Office of Fishery Management, Division of Fishery, Department of Industry, Shizuoka Prefectural Government

— Fisheries Administration Division, Department of Agriculture, Forestry and Fisheries, Aichi Prefectural Government

— Fisheries Resource Office, Department of Agriculture, Fisheries, Commerce and Industry, Mie Prefectural Government

— Fisheries Division, Department of Agriculture, Forestry and Fisheries, Kyoto Prefectural Government

— Fisheries Office, Kyoto Prefectural Government

— Fisheries Division, Department of Environment, Agriculture, Forestry and Fisheries, Osaka Prefectural Government

— Fisheries Division, Agriculture, Forestry and Fisheries Bureau, Agriculture and Environmental Department, Hyogo Prefectural Department

— Kobe Agriculture, Forestry and Fisheries Office, Kobe District Administration Office, Hyogo Prefectural Government

— Kakogawa Agriculture, Forestry and Fisheries Office, Higashi- Harima District Administration Office, Hyogo Prefectural Government

— Himeji Agriculture, Forestry and Fisheries Office, Naka-Harima District Administration Office, Hyogo Prefectural Government

— Koto Agriculture, Forestry and Fisheries Office, Nishi-Harima District Administration Office, Hyogo Prefectural Government

— Tajima Fisheries Office, Tajima District Administration Office, Hyogo Prefectural Government

— Sumoto Agriculture, Forestry and Fisheries Office, Awaji District Administration Office, Hyogo Prefectural Government

— Wakayama Prefectural Government

— Kaisou Promotions Bureau, Wakayama Prefectural Government

— Arida Promotions Bureau, Wakayama Prefectural Government

— Hidaka Promotions Bureau, Wakayama Prefectural

— Nishimuro Promotion Bureau, Wakayama Prefectural Government

— Higashimuro Promotion Bureau, Wakayama Prefectural Government

— Fishery Division, Fishery Development Bureau, Department of Agriculture, Forestry and Fishery, Tottori Prefectural Government

— Fisheries Division, Department of Agriculture, Forestry and Fisheries, Shimane Prefectural Government

— Fisheries Office, Oki Branch Office, Shimane Prefectural Government

— Matsue Fisheries Office, Shimane Prefectural Government

— Hamada Fisheries Office, Shimane Prefectural Government

— Okayama Prefectural Government



— Hiroshima Prefectural Government

— Fisheries Promotion Division, Yamaguchi Prefectural Government

— Fisheries Division, Agriculture, Forestry and Fisheries Department, Tokushima Prefectural Government

— Fisheries Division, Agricultural Administration and Fisheries Department, Kagawa Prefectural Government

— Fisheries Promotion Division, Fisheries Bureau, Agriculture, Forestry and Fisheries Department, Ehime Prefectural Government

— Fisheries Management Division, Kochi Prefectural Government

— Fishery Administration Division, Fishery Bureau, Department of Agriculture, Forestry and Fisheries, Fukuoka Prefectural Government

— Fisheries Division, Saga Prefectural Government

— Resource Management Division, Fisheries Department, Nagasaki Prefectural Government

— Department of Agriculture, Forestry and Fisheries, Kumamoto Prefectural Government

— Tamana Regional Promotion Bureau, Kumamoto Prefectural Government

— Yatsushiro Regional Promotion Bureau, Kumamoto Prefectural Government

— Amakusa Regional Promotion Bureau, Kumamoto Prefectural Government

— Oita Prefectural Government

— Fisheries Administration Division, Agriculture and Fisheries Department, Miyazaki Prefectural Government

— Fisheries Promotion Division, Kagoshima Prefectural Government

— Fisheries Division, Department of Agriculture, Forestry and Fisheries Department, Miyazaki Prefectural Government


— Fisheries Division, Department of Agriculture, Forestry and Fisheries, Okinawa Prefectural Government

— Agriculture, Forestry and Fisheries Management Division, Miyako Regional Agriculture Forestry and Fisheries Promotions Center, Okinawa Prefectural Government

— Agriculture, Forestry and Fisheries Management Division, Yaeyama Regional Agriculture, Forestry and Fisheries Promotions Centre, Okinawa Prefectural Government

b):

— Fisheries Management Division, Bureau of Fisheries, Department of Fisheries and Forestry, Hokkaido Government

— Aomori Prefectural Government

— Hachinohe Fisheries Office, Sanpachi District Administration Office, Aomori Prefectural Government

— Mutsu Fisheries Office, Department of Agriculture, Forestry and Fisheries, Seihoku District Administration Office, Aomori Prefectural Government

— Ajigasawa Fisheries Office, Department of Agriculture, Forestry and Fisheries, Seihoku District Administration Office, Aomori Prefectural Government












— Fishery Office, Fukushima Prefectural Government



— Fishery section, Agriculture, Forestry and Fishery Division, Bureau of Industrial and Labour Affairs, Tokyo Metropolitan Government



— Promotion Division, Agriculture, Forestry and Fisheries Promotion Department, Sado Regional Promotion Bureau, Niigata Prefectural Government

— Fisheries and Fishing Port Division, Toyama Prefectural Government








— Fisheries Office, Kyoto Prefectural Government



— Kobe Agriculture, Forestry and Fisheries Office, Kobe District Administration Office, Hyogo Prefectural Government

— Kakogawa Agriculture, Forestry and Fisheries Office, Higashi- Harima District Administration Office, Hyogo Prefectural Government

— Himeji Agriculture, Forestry and Fisheries Office, Naka-Harima District Administration Office, Hyogo Prefectural Government

— Koto Agriculture, Forestry and Fisheries Office, Nishi-Harima District Administration Office, Hyogo Prefectural Government

— Tajima Fisheries Office, Tajima District Administration Office, Hyogo Prefectural Government

— Sumoto Agriculture, Forestry and Fisheries Office, Awaji District Administration Office, Hyogo Prefectural Government


— Kaisou Promotions Bureau, Wakayama Prefectural Government

— Arida Promotions Bureau, Wakayama Prefectural Government

— Hidaka Promotions Bureau, Wakayama Prefectural Government

— Nishimuro Promotion Bureau, Wakayama Prefectural Government

— Higashimuro Promotion Bureau, Wakayama Prefectural Government





— Fisheries Office, Oki Branch Office, Shimane Prefectural Government

— Matsue Fisheries Office, Shimane Prefectural Government

— Hamada Fisheries Office, Shimane Prefectural Government












— Tamana Regional Promotion Bureau, Kumamoto Prefectural Government

— Yatsushiro Regional Promotion Bureau, Kumamoto Prefectural Government

— Amakusa Regional Promotion Bureau, Kumamoto Prefectural Government




— Fisheries Division, Department of Agriculture, Forestry and Fisheries Department, Miyazaki Prefectural Government


— Fisheries Division, Department of Agriculture, Forestry and Fisheries, Okinawa Prefectural Government

— Agriculture, Forestry and Fisheries Management Division, Miyako Regional Agriculture Forestry and Fisheries Promotions Center, Okinawa Prefectural Government

— Agriculture, Forestry and Fisheries Management Division, Yaeyama Regional Agriculture, Forestry and Fisheries Promotions Centre, Okinawa Prefectural Government

— Fishery Agency, Ministry of Agriculture, Forestry and Fisheries,

— Iwate Regional Marine Fisheries Management Commission

— Fisheries Division, Tsu Agriculture, Forestry, Fisheries, Commerce, Industry and Environment Office, Mie Prefectural Government

— Fisheries Division, Ise Agriculture, Forestry, Fisheries, Commerce, Industry and Environment Office, Mie Prefectural Government

— Fisheries Division, Owase Agriculture, Forestry, Fisheries, Commerce, Industry and Environment Office, Mie Prefectural Government


c), e), f), g):

— Fisheries Agency, Ministry of Agriculture, Forestry and Fisheries

d):

— Fisheries Management Division, Bureau of Fisheries, Department of Fisheries and Forestry, Hokkaido Government



— Fisheries Agency, Ministry of Agriculture, Forestry and Fisheries

— Aomori Prefectural Government


— Iwate Regional Marine Fisheries Management Commission











— Fishery section, Agriculture, Forestry and Fishery Division, Bureau of Industrial and Labour Affairs, Tokyo Metropolitan Government



— Fisheries and Fishing Port Division, Toyama Prefectural Governement





























— Fisheries Division, Department of Agriculture, Forestry and Fisheries Department, Okinawa Prefectural Government

KENYA a):

— Kenya Maritime Authority

b) to g):

— Ministry of Fisheries Development

KOREA a), b), d), f), g):

— Ministry for Food, Agriculture, Forestry and Fisheries

c), e):

— National Fisheries Products Quality Inspection Service and its 13 branch offices:

— Seoul Branch Office

— Incheon Branch Office

— Janghang Branch Office

— Yeosu Branch Office

— Mokpo Branch Office

— Wando Branch Office

— Jeju Branch Office

— Busan Branch Office

— Tongyoung Branch Office

— Pohang Branch Office

— Gangneung Branch Office

— Incheon International Airport Branch Office

— Pyeongtaek Branch Office

MADAGASCAR a):

— Agence Portuaire Maritime et Fluviale

b):

— Ministère chargé de la Pêche

c), d):

— Centre de Surveillance des Pêches

e), f), g):

— Direction Générale de la Pêche et des Ressources Halieutiques



MALAYSIA a), b): — Department of Fisheries Malaysia

— Department of Fisheries Sabah

d): — Department of Fisheries Malaysia

— Department of Fisheries Sabah

— Fisheries Development Authority of Malaysia — Malaysian Quarantine and Inspection Services

— Royal Malaysian Police

— Royal Malaysian Navy e), f):

— Department of Fisheries, Malaysia

g): — Department of Fisheries Malaysia

— Ministry of Agriculture and Agro-based

MALDIVES a):

— Ministry of Housing, Transport and Environment b):

— Ministry of Fisheries and Agriculture

— Ministry of Economic Development

c), e), f), g): — Ministry of Fisheries and Agriculture

d):

— Coast Guard, Maldives National Defence Force — Maldives Police Service

MAURITIUS a) to g):

— Fishery Division, Ministry of Agro Industry, Food Production and Security

MONTENEGRO a):

— Ministry of Transport, Maritime Affairs and Telecommunications

b) to g): — Ministry of Agriculture, Forestry and Water management

MEXICO a):

— Director General de Planeación y Evaluación

b): — Director General de ordenamiento Pesquero y Acuícola

c):

— Oficinas de SAGARPA-CONAPESCA en los estados de la Republica mexicana d), e):

— Director General de Inspección y Vigilancia

f): — Comisión Nacional de Acuacultura y Pesca

g):

— Dirección General de Planeación, Programación y Evaluación

MOROCCO a), b), e), f):

— Direction des Pêches Maritimes et de l'Aquaculture c):

— Délégations des Pêches Maritimes de Jebha, Nador, Al Hoceima, M'diq, Tanger, Larache, Kenitra-Mehdia, Mohammedia, Casablanca, El Jadida, Safi, Essaouira, Agadir, Sidi Ifni, Tan- Tan, Laâyoune, Boujdour, Dakhla



d): — Direction des Pêches Maritimes

— Délégations des Pêches Maritimes de Jebha, Nador, Al Hoceima, M'diq, Tanger, Larache, Kenitra-Mehdia, Mohammedia, Casablanca, El Jadida, Safi, Essaouira, Agadir, Sidi Ifni, Tan- Tan, Laâyoune, Boujdour, Dakhla

g):

— Secrétariat général du Département de la Pêche Maritime

MOZAMBIQUE a):

— National Marine Institute b) to g):

— National Directorate of Fisheries Administration

NAMIBIA a):

— Ministry of Works, Transport and Communication

b), d), f), g): — Ministry of Fisheries and Marine Resources

c), e):

— Ministry of Fisheries and Marine Resources (Walvis Bay) — Ministry of Fisheries and Marine Resources (Lüderitz)

NEW ZEALAND a), b), c), d), f), g):

— Ministry of Fisheries

e): — New Zealand Food Safety Authority

— Ministry of Fisheries

NICARAGUA a):

— Dirección General de Transporte Acuático del Ministerio de Transporte e Infraestructura

b), d), f), g): — Presidente Ejecutivo, Instituto Nicaragüense de la Pesca y Acuicultura (INPESCA)

c):

— Delegaciones Departamentales de INPESCA: Puerto Cabezas, Chinandega, Bluefields, Rivas e):

— Dirección de Monitoreo, Viligancia y Control, INPESCA

NORWAY a), b), c), e), f), g):

— Directorate of Fisheries d):

— Directorate of Fisheries

— The Norwegian Coastguard — The Police and the Public Prosecuting Authority

OMAN a) to f): — Directorate General of Fisheries Resources Department, Ministry of Fish Wealth

PAKISTAN a):

— Mercantile Marine Department

b), d): — Marine Fisheries Department

— Directorate of Fisheries of Balochistan

— Directorate of Fisheries of Sindh c), e), f):

— Marine Fisheries Department

g): — Ministry of Livestock and Dairy Development



SENEGAL a):

— Agence Nationale des Affaires Maritimes

b): — Ministre de la Pêche

c):

— Directeur des Industries de Transformation de la Pêche

d), e), f), g): — Directeur de la Protection et de la Surveillance des Pêches

SEYCHELLES a):

— Seychelles Maritime Safety Administration

b): — Seychelles Licensing Authority

c) to g):

— Seychelles Fishing Authority

SOLOMON ISLANDS

a): — Marine Division, Ministry of Infrastructure and Development (MID)

b) to g):

— Ministry of Fisheries and Marine Resources (MFMR)

SOUTH AFRICA a) to g): — Marine and Coastal Management, Department of Environmental Affairs

SRI LANKA a) to g): — Department of Fisheries and Aquatic Resources

ST HELENA a):

— Registrar of Shipping

b), d), e), f), g): — Senior Fisheries Officer, Directorate of Fisheries

c):

— H.M. Customs, Government of St. Helena

SURINAME a): — Maritime Authority Suriname

b) to g):

— Ministry of Agriculture, Animal Husbandry and Fisheries

TAIWAN a):

— Council of Agriculture b) to g):

— Fisheries Agency

TANZANIA a) to g):

— Director of Fisheries, Ministry of Livestock Development and Fisheries

THAILAND a) to g): — The Department of Fisheries of Thailand

TURKEY a), b):

— 81 Provincial Directorates of the Ministry of Agriculture and Rural Affairs

c): — General Directorate for Protection and Conservation

— 81 Provincial Directorates of the Ministry of Agriculture and Rural Affairs

d): — General Directorate for Protection and Conservation



— 81 Provincial Directorates of the Ministry of Agriculture and Rural Affairs — Turkish Coast Guard Command

e), f), g):

— General Directorate for Protection and Conservation

URUGUAY a) to g):

— Dirección Nacional de Recursos Acuáticos

UNITED STATES a):

— United States Coast Guard b) to g):

— National Marine Fisheries Service

VIETNAM a), b), c): — Department of Capture Fisheries and Resources Protection (DECAFIREP) and Department of

Capture Fisheries and Resources Protection of Provinces Division

d):

— Inspection of DECAFIREP and Inspection of Agriculture and Rural Development Division belonging to the provinces

e), f), g): — Department of Capture Fisheries and Resources Protection

VENEZUELA a) to g):

— Presidente del Instituto Socialista de la Pesca y Acuicultura


V

(Announcements)

ADMINISTRATIVE PROCEDURES

COMMISSION

CALL FOR PROPOSALS 2010 — EACEA/31/09

EU-US Cooperation in Higher Education and Vocational Training

(2009/C 323/10)

ATLANTIS:

Actions for Transatlantic Links and Academic Networks in Training and Integrated Studies

1. Objectives and Description

The general objectives are to promote mutual understanding between the peoples of the European Union and the United States of America including broader knowledge of their languages, cultures and institutions and to improve the quality of human resource development in both the European Union and the United States of America;

2. Eligible applicants

Submission of grant requests under this call is open to higher education institutions and to vocational education and training institutions. For Policy Oriented Measures, the call is also open to other organisations such as accreditation agencies, education agencies or organisations, private companies, industry and business groups, non-governmental organisations, research institutes and professional bodies. Eligible applicants must be established in one of the countries of the European Union.

A consortium applying for the Atlantis programme must meet the following membership criteria:

— Transatlantic Degree Projects must include one of two consortium/membership options:

1. a minimum of two EU institutions from different EU Member States and one U.S. institution,

or

2. a minimum of two EU institutions from different EU Member States and two U.S. institutions (from the same or different States).

— Excellence in Mobility projects must include at least two EU institutions from different EU Member States and two U.S. institutions (from the same or different States). Additional partners above the minimum number do not increase the budget.

— Policy-oriented Measures must include at least two EU institutions from different EU Member States and two U.S. institutions (from the same or different States). Additional partners above the minimum number do not increase the budget.

3. Eligible actions and duration

There are three types of actions under this call, namely:


Action1 — Transatlantic Degree Consortia Projects

This Action provides support for consortia of EU and U.S. higher education institutions (hereafter called ‘consortium’) to implement dual/double or joint degree programs referred to in the present document as ‘Transatlantic Degrees’. Support includes mobility grants for students and members of the academic and administrative staff (‘faculty’).

Action2 — Excellence in Mobility Projects

This Action provides funding for international curriculum development projects that involve short-term transatlantic mobility not directly related to the award of a joint or dual/double degree. Support includes mobility grants for students and members of the academic and administrative staff (‘faculty’).

Action3 — Policy-oriented Measures

This Action provides support to multilateral EU-U.S. projects and activities designed to enhance collaboration in the higher education and vocational training field.

The maximum duration of projects varies between 24 and 48 months depending on the action. Activities are planned to start between 1.9.2010 and 31.12.2010 and depending on the programme action, finish two or four years later.

Transatlantic Degree projects 48 months

Excellence in Mobility 48 months

Policy-oriented Measures 24 months

4. Award criteria

Award Criteria for Transatlantic Degree Projects and Excellence in Mobility Projects

The following quality criteria will be applied to determine the overall quality score of each eligible proposal:

The significance of the proposed project, (representing 30 % of the total score)

The quality of the proposed project design, (representing 70 % of the total score).

Award Criteria for Policy-oriented Measures

The following quality criteria will be applied to determine the overall quality score of each eligible proposal:

The significance of the proposed project, (representing 30 % of the total score)

The quality of the project design, (representing 70 % of the total score).

A more detailed description on the award criteria can be found in the programme guide.

During the selection priority will be given to (provided the proposal represent sufficient quality):

— institutions and departments that have not been funded as Lead partners during the two previous Atlantis selection rounds,

— proposals focusing on vocational education and training.

5. Budget

The budget available on the EU side amounts to approximately EUR 5,5 million. For U.S. institutions comparable funding will be provided. It is anticipated that:

— eight to ten Action1 projects, with a maximum of EUR 428 000 will be financed,

— five to seven Action 2 projects with a maximum on EUR 180 000, and

— five to seven Action 3 projects, with a maximum of EUR 70 000 will be financed.


6. Deadline

Applications have to be submitted both to the EU and to the U.S.A. no later than 8 April 2010.

The European applicant must send the application to the Education, Audiovisual and Culture Executive Agency, to the following address:

The Education, Audiovisual and Culture Executive Agency EU-US Call 2010 Office: BOUR 02/17 Avenue du Bourget 1 1140 Bruxelles/Brussel BELGIQUE/BELGIË

Applications on behalf of the EU lead institution must be submitted on the correct form, duly completed, signed by the person authorised to enter into legally binding commitments on behalf of the applicant organization and dated.

EU applicants seeking for further information can contact the Education, Audiovisual and Culture Executive Agency at the e-mail address: [email protected]

The American applicant should send the application to the U.S.A. and information and instructions in the application packet can be found at: http://e-grants.ed-gov

For U.S. applicants seeking further information, please contact:

Frank Frankfort, Ph.D. EU-U.S. Atlantis Program Coordinator U.S. Department of Education Fund for the Improvement of Postsecondary Education (FIPSE) 1990 K Street, NW, 6th Floor Washington, D.C. 20006-8544 UNITED STATES OF AMERICA

Tel. 202-502-7513 Fax 202-502-7877 [email protected]

7. Further information

The text of the programme guide and the application forms are available on the following website: http://ec. europa.eu/education/programmes/eu-usa/index_en.html

Applications must comply with the requirements set out in the programme guide and be submitted using the form provided.


mailto:[email protected]

http://e-grants.ed-gov

mailto:[email protected]

http://ec.europa.eu/education/programmes/eu-usa/index_en.html

http://ec.europa.eu/education/programmes/eu-usa/index_en.html

PROCEDURES RELATING TO THE IMPLEMENTATION OF THE COMPETITION POLICY

COMMISSION

Prior notification of a concentration

(Case COMP/M.5718 — Bregal Capital/Englefield Capital)

Candidate case for simplified procedure


(2009/C 323/11)

1. On 21 December 2009, the Commission received a notification of a proposed concentration pursuant to Article 4 of Council Regulation (EC) No 139/2004 ( 1 ) by which the undertaking Bregal Capital Limited (‘Bregal Capital’, UK) controlled by COFRA Holding AG (‘COFRA’, Switzerland) acquires within the meaning of Article 3(1)(b) of the Regulation control of the whole of the undertaking Englefield Capital LLP (‘Englefiel’, UK) by way of purchase of shares.

2. The business activities of the undertakings concerned are:

— for Bregal Capital: a limited liability corporate investment vehicle,

— for COFRA: retail, real estate, financial services, investment management and renewable energy,

— for Englefield: a manager of several private equity funds, making investments in middle market companies across Europe in a range of industry sectors.

3. On preliminary examination, the Commission finds that the notified transaction could fall within the scope of Regulation (EC) No 139/2004. However, the final decision on this point is reserved. Pursuant to the Commission Notice on a simplified procedure for treatment of certain concentrations under Council Regulation (EC) No 139/2004 ( 2 ) it should be noted that this case is a candidate for treatment under the procedure set out in the Notice.

4. The Commission invites interested third parties to submit their possible observations on the proposed operation to the Commission.

Observations must reach the Commission not later than 10 days following the date of this publication. Observations can be sent to the Commission by fax (+32 22964301 or 22967244) or by post, under reference number COMP/M.5718 — Bregal Capital/Englefield Capital, to the following address:

European Commission Directorate-General for Competition Merger Registry 1049 Bruxelles/Brussel BELGIQUE/BELGIË


( 1 ) OJ L 24, 29.1.2004, p. 1. ( 2 ) OJ C 56, 5.3.2005, p. 32.

V Announcements

ADMINISTRATIVE PROCEDURES

Commission

2009/C 323/10 Call for proposals 2010 — EACEA/31/09 — EU-US Cooperation in Higher Education and Vocational Training . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 42

PROCEDURES RELATING TO THE IMPLEMENTATION OF THE COMPETITION POLICY

Commission

2009/C 323/11 Prior notification of a concentration (Case COMP/M.5718 — Bregal Capital/Englefield Capital) — Candidate case for simplified procedure ( 1 ) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 45

EN

Notice No Contents (continued)

( 1 ) Text with EEA relevance

Page



2009 SUBSCRIPTION PRICES (excluding VAT, including normal transport charges)

EU Official Journal, L + C series, paper edition only 22 official EU languages EUR 1 000 per year (*) EU Official Journal, L + C series, paper edition only 22 official EU languages EUR 100 per month (*) EU Official Journal, L + C series, paper + annual CD-ROM 22 official EU languages EUR 1 200 per year EU Official Journal, L series, paper edition only 22 official EU languages EUR 700 per year EU Official Journal, L series, paper edition only 22 official EU languages EUR 70 per month EU Official Journal, C series, paper edition only 22 official EU languages EUR 400 per year EU Official Journal, C series, paper edition only 22 official EU languages EUR 40 per month EU Official Journal, L + C series, monthly CD-ROM (cumulative) 22 official EU languages EUR 500 per year Supplement to the Official Journal (S series), tendering procedures for public contracts, CD-ROM, two editions per week

multilingual: 23 official EU languages

EUR 360 per year (= EUR 30 per month)

EU Official Journal, C series — recruitment competitions Language(s) according to competition(s)

EUR 50 per year

(*) Sold in single issues: up to 32 pages: EUR 6 from 33 to 64 pages: EUR 12 over 64 pages: Priced individually.

Subscriptions to the Official Journal of the European Union, which is published in the official languages of the European Union, are available for 22 language versions. The Official Journal comprises two series, L (Legislation) and C (Information and Notices). A separate subscription must be taken out for each language version. In accordance with Council Regulation (EC) No 920/2005, published in Official Journal L 156 of 18 June 2005, the institutions of the European Union are temporarily not bound by the obligation to draft all acts in Irish and publish them in that language. Irish editions of the Official Journal are therefore sold separately. Subscriptions to the Supplement to the Official Journal (S Series — tendering procedures for public contracts) cover all 23 official language versions on a single multilingual CD-ROM. On request, subscribers to the Official Journal of the European Union can receive the various Annexes to the Official Journal. Subscribers are informed of the publication of Annexes by notices inserted in the Official Journal of the European Union.

Sales and subscriptions

Priced publications issued by the Publications Office are available from our commercial distributors. The list of commercial distributors is available at: http://publications.europa.eu/others/agents/index_en.htm

EUR-Lex (http://eur-lex.europa.eu) offers direct access to European Union legislation free of charge. The Official Journal of the European Union can be consulted on this website, as can the Treaties,

legislation, case-law and preparatory acts.

For further information on the European Union, see: http://europa.eu EN

of the european union · information from european union institutions and bodies commission 2009/c...

Documents